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Investigation in ST-Elevation Acute Coronary
Syndrome
RIVAL Radial Versus Femoral Access for Coronary
intervention
RV right ventricle/ventricular
SaO2 arterial oxygen saturation
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SBP systolic blood pressure
s.c. subcutaneous
SGLT2 sodium-glucose co-transporter-2
SPECT single-photon emission computed tomography
STEMI ST-segment elevation myocardial infarction
STREAM STrategic Reperfusion Early After Myocardial
infarction
TIMI Thrombolysis In Myocardial Infarction
TNK-tPA Tenecteplase tissue plasminogen activator
TOTAL Trial of Routine Aspiration Thrombectomy
with PCI versus PCI Alone in Patients with
STEMI
tPA tissue plasminogen activator
UFH unfractionated heparin
VALIANT VALsartan In Acute myocardial iNfarcTion
VF ventricular fibrillation
VT ventricular tachycardia
24/7 24 h a day, seven days a week
1. Preamble
Guidelines summarize and evaluate available evidence with the aim of
assisting health professionals in selecting the best management strat-
egies for an individual patient with a given condition. Guidelines and
their recommendations should facilitate decision making of health
professionals in their daily practice. However, the final decisions con-
cerning an individual patient must be made by the responsible health
professional(s) in consultation with the patient and caregiver as
appropriate.
A great number of guidelines have been issued in recent years by
the European Society of Cardiology (ESC), as well as by other soci-
eties and organisations. Because of the impact on clinical practice,
quality criteria for the development of guidelines have been
established in order to make all decisions transparent to the user.
The recommendations for formulating and issuing ESC Guidelines
can be found on the ESC website (https://www.escardio.org/
Guidelines/Clinical-Practice-Guidelines/Guidelines-development/
Writing-ESC-Guidelines). ESC Guidelines represent the official posi-
tion of the ESC on a given topic and are regularly updated.
Members of this Task Force were selected by the ESC, including
representation from its relevant ESC sub-specialty groups, in order
to represent professionals involved with the medical care of patients
with this pathology. Selected experts in the field undertook a com-
prehensive review of the published evidence for management of a
given condition according to ESC Committee for Practice Guidelines
(CPG) policy. A critical evaluation of diagnostic and therapeutic pro-
cedures was performed, including assessment of the risk–benefit
ratio. The level of evidence and the strength of the recommendation
of particular management options were weighed and graded accord-
ing to predefined scales, as outlined in Tables 1 and 2.
The experts of the writing and reviewing panels provided declara-
tion of interest forms for all relationships that might be perceived as
real or potential sources of conflicts of interest. These forms were
compiled into one file and can be found on the ESC website (http://
www.escardio.org/guidelines). Any changes in declarations of interest
that arise during the writing period were notified to the ESC and
updated. The Task Force received its entire financial support from
the ESC without any involvement from the healthcare industry.
The ESC CPG supervises and coordinates the preparation of new
ESC Guidelines. The Committee is also responsible for the endorse-
ment process of these Guidelines. The ESC Guidelines undergo
extensive review by the CPG and external experts. After appropriate
revisions the Guidelines are approved by all the experts involved in
the Task Force. The finalized document is approved by the CPG for
publication in the European Heart Journal. The Guidelines were
developed after careful consideration of the scientific and medical
knowledge and the evidence available at the time of their dating.
Table 1 Classes of recommendations
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The task of developing ESC Guidelines also includes the creation
of educational tools and implementation programmes for the recom-
mendations including condensed pocket guideline versions, summary
slides, booklets with essential messages, summary cards for non-
specialists and an electronic version for digital applications (smart-
phones, etc.). These versions are abridged and thus, if needed, one
should always refer to the full text version, which is freely available
via the ESC website and hosted on the EHJ website. The National
Societies of the ESC are encouraged to endorse, translate and imple-
ment all ESC Guidelines. Implementation programmes are needed
because it has been shown that the outcome of disease may be
favourably influenced by the thorough application of clinical
recommendations.
Surveys and registries are needed to verify that real-life daily prac-
tice is in keeping with what is recommended in the guidelines, thus
completing the loop between clinical research, writing of guidelines,
disseminating them and implementing them into clinical practice.
Health professionals are encouraged to take the ESC Guidelines
fully into account when exercising their clinical judgment, as well as in
the determination and the implementation of preventive, diagnostic
or therapeutic medical strategies. However, the ESC Guidelines do
not override in any way whatsoever the individual responsibility of
health professionals to make appropriate and accurate decisions in
consideration of each patient’s health condition and in consultation
with that patient or the patient’s caregiver where appropriate and/or
necessary. It is also the health professional’s responsibility to verify
the rules and regulations applicable to drugs and devices at the time
of prescription.
2. Introduction
Updates on the management of patients presenting with ST-segment
elevation myocardial infarction (STEMI) should be based on sound
evidence, derived from well-conducted clinical trials whenever possi-
ble, or motivated expert opinion when needed. It must be recognized
that, even when excellent clinical trials have been undertaken, the
results are open to interpretation and treatments may need to be
adapted to take account of clinical circumstances and resources.
The present Task Force has made an important effort to be as
aligned as possible with the other ESC Guidelines1–6 and consensus
documents, including the simultaneously published update on dual
antiplatelet therapy (DAPT),7 for consistency in the ESC Guidelines
strategy. The levels of evidence and the strengths of recommenda-
tion of particular treatment options were weighed and graded
according to pre-defined scales, as outlined in Tables 1 and 2. Despite
recommendations with a level of evidence being based on expert
opinion, this Task Force decided to add references to guide the
reader regarding data that were taken into consideration for these
decisions in some cases.
2.1 Definition of acute myocardial
infarction
The term acute myocardial infarction (AMI) should be used when
there is evidence of myocardial injury (defined as an elevation of car-
diac troponin values with at least one value above the 99th percentile
upper reference limit) with necrosis in a clinical setting consistent
with myocardial ischaemia.8 For the sake of immediate treatment
strategies such as reperfusion therapy, it is usual practice to designate
patients with persistent chest discomfort or other symptoms sugges-
tive of ischaemia and ST-segment elevation in at least two contiguous
leads as STEMI. In contrast, patients without ST-segment elevation at
presentation are usually designated as having a non-ST-segment ele-
vation myocardial infarction (MI) (NSTEMI) and separate guidelines
have recently been developed for these.2 Some patients with MI
develop Q-waves (Q-wave MI), but many do not (non-Q-wave MI).
In addition to these categories, MI is classified into various types,
based on pathological, clinical, and prognostic differences, along with
different treatment strategies (see the Third Universal Definition of
MI document,8 which will be updated in 2018). Despite the fact that
the majority of STEMI patients are classified as a type 1 MI (with evi-
dence of a coronary thrombus), some STEMIs fall into other MI
types.8 MI, even presenting as STEMI, also occurs in the absence of
obstructive coronary artery disease (CAD) on angiography.9–12 This
type of MI is termed ‘myocardial infarction with non-obstructive cor-
onary arteries’ (MINOCA) and is discussed in Chapter 9 of this
document.
2.2 Epidemiology of ST-segment
elevation myocardial infarction
Worldwide, ischaemic heart disease is the single most common cause
of death and its frequency is increasing. However, in Europe, there
has been an overall trend for a reduction in ischaemic heart disease
mortality over the past three decades.13 Ischaemic heart disease now
accounts for almost 1.8 million annual deaths, or 20% of all deaths in
Europe, although with large variations between countries.14
The relative incidences of STEMI and NSTEMI are decreasing and
increasing, respectively.15,16 Probably the most comprehensive
European STEMI registry is found in Sweden, where the incidence
rate of STEMI was 58 per 100 000 per year in 2015.17 In other
European countries, the incidence rate ranged from 43 to 144 per
100 000 per year.18 Similarly, the reported adjusted incidence rates
from the USA decreased from 133 per 100 000 in 1999 to 50 per
100 000 in 2008, whereas the incidence of NSTEMI remained con-
stant or increased slightly.19 There is a consistent pattern for STEMI
to be relatively more common in younger than in older people, and
more common in men than in women.17,20
The mortality in STEMI patients is influenced by many factors,
among them advanced age, Killip class, time delay to treatment,
Table 2 Levels of evidence
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presence of emergency medical system (EMS)-based STEMI net-
works, treatment strategy, history of MI, diabetes mellitus, renal fail-
ure, number of diseased coronary arteries, and left ventricular
ejection fraction (LVEF). Several recent studies have highlighted a fall
in acute and long-term mortality following STEMI in parallel with
greater use of reperfusion therapy, primary percutaneous coronary
intervention (PCI), modern antithrombotic therapy, and secondary
prevention.14,21,22 Nevertheless, mortality remains substantial; the in-
hospital mortality of unselected patients with STEMI in the national
registries of the ESC countries varies between 4 and 12%,23 while
reported 1-year mortality among STEMI patients in angiography
registries is approximately 10%.24,25
Although ischaemic heart disease develops on average 7–10 years
later in women compared with men, MI remains a leading cause of
death in women. Acute coronary syndrome (ACS) occurs three to
four times more often in men than in women below the age of
60 years, but after the age of 75, women represent the majority of
patients.26 Women tend to present more often with atypical symp-
toms, up to 30% in some registries,27 and tend to present later than
men.28,29 It is therefore important to maintain a high degree of aware-
ness for MI in women with potential symptoms of ischaemia. Women
also have a higher risk of bleeding complications with PCI. There is an
ongoing debate regarding whether outcomes are poorer in women,
with several studies indicating that a poorer outcome is related to
older age and more comorbidities among women suffering MI.26,30,31
Some studies have indicated that women tend to undergo fewer inter-
ventions than men and receive reperfusion therapy less fre-
quently.26,32,33 These guidelines aim to highlight the fact that women
and men receive equal benefit from a reperfusion strategy and STEMI-
related therapy, and that both genders must be managed in a similar
fashion.
3. What is new in the 2017
version?
patients
stenting
Figure 1 What is new in 2017 STEMI Guidelines. BMS = bare metal stent; DES = drug eluting stent; IRA = infarct related artery; i.v. = intravenous;
LDL = low-density lipoprotein; PCI = percutaneous coronary intervention; SaO2 = arterial oxygen saturation; STEMI = ST-elevation myocardial
infarction; TNK-tPA = Tenecteplase tissue plasminogen activator. For explanation of trial names, see list of.
aOnly for experienced radial operators.
bBefore hospital discharge (either immediate or staged).
cRoutine thrombus aspiration (bailout in certain cases may be considered).
dIn 2012 early discharge was considered after 72h, in 2017 early discharge is 48–72h.
eIf symptoms or haemodynamic instability IRA should be opened regardless time from symptoms onset.
In left and mid panels, below each recommendation, the most representative trial (acronym and reference) driving the indication is
mentioned.
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4.1 Initial diagnosis
Management—including diagnosis and treatment—of STEMI starts
from the point of first medical contact (FMC, defined in Table 4). It is
recommended that a regional reperfusion strategy should be estab-
lished to maximize efficiency.
A working diagnosis of STEMI (called the ‘STEMI diagnosis’
throughout this document) must first be made. This is usually based
on symptoms consistent with myocardial ischaemia (i.e. persistent
chest pain) and signs [i.e. 12-lead electrocardiogram (ECG)].
Important clues are a history of CAD and radiation of pain to the
neck, lower jaw, or left arm. Some patients present with less-typical
symptoms such as shortness of breath, nausea/vomiting, fatigue, pal-
pitations, or syncope.34 A reduction in chest pain after nitroglycerin
(glyceryl trinitrate) administration can be misleading and is not rec-
ommended as a diagnostic manoeuvre.35 In cases of symptom relief
after nitroglycerin administration, another 12-lead ECG must be
obtained. A complete normalization of the ST-segment elevation
after nitroglycerin administration, along with complete relief of symp-
toms, is suggestive of coronary spasm, with or without associated MI.
In these cases, an early coronary angiography (within 24 h) is recom-
mended. In cases of recurrent episodes of ST-segment elevation or
chest pain, immediate angiography is required.
It is recommended to initiate ECG monitoring as soon as possible
in all patients with suspected STEMI in order to detect life-
threatening arrhythmias and allow prompt defibrillation if indicated.
When a STEMI is suspected, a 12-lead ECG must be acquired and
interpreted as soon as possible at the time of FMC to facilitate early
STEMI diagnosis and triage.36–40
In patients with a clinical suspicion of myocardial ischaemia and ST-
segment elevation, reperfusion therapy needs to be initiated as soon
as possible.41 If the ECG is equivocal or does not show evidence to
support the clinical suspicion of MI, ECGs should be repeated and,
when possible compared with previous recordings. If interpretation
of pre-hospital ECG is not possible on-site, field transmission of the
ECG is recommended.42
ECG criteria are based on changes of electrical currents of the
heart (measured in millivolts). Standard calibration of the ECG is
10mm/mV. Therefore 0.1 mV equals to 1 mm square on the vertical
axis. For simplicity, in this document ECG deviations are expressed in
mm following the standard calibration.
In the proper clinical context, ST-segment elevation (measured at
the J-point) is considered suggestive of ongoing coronary artery acute
occlusion in the following cases: at least two contiguous leads with
ST-segment elevation  2.5 mm in men < 40 years, 2 mm in men
 40 years, or 1.5 mm in women in leads V2–V3 and/or  1 mm in
the other leads [in the absence of left ventricular (LV) hypertrophy
or left bundle branch block LBBB)].8 In patients with inferior MI, it is
recommended to record right precordial leads (V3R and V4R) seek-
ing ST-segment elevation, to identify concomitant right ventricular
(RV) infarction.8,43 Likewise, ST-segment depression in leads V1–V3
suggests myocardial ischaemia, especially when the terminal T-wave
is positive (ST-segment elevation equivalent), and confirmation by
concomitant ST-segment elevation  0.5 mm recorded in leads
V7–V9 should be considered as a means to identify posterior MI.
8
The presence of a Q-wave on the ECG should not necessarily change
the reperfusion strategy decision.
The ECG diagnosis may be more difficult in some cases, which
nevertheless deserve prompt management and triage. Among these:
Bundle branch block. In the presence of LBBB, the ECG diagno-
sis of AMI is difficult but often possible if marked ST-segment abnor-
malities are present. Somewhat complex algorithms have been offered
to assist the diagnosis,50,51 but they do not provide diagnostic cer-
tainty.52 The presence of concordant ST-segment elevation (i.e. in
leads with positive QRS deflections) appears to be one of the best indi-
cators of ongoing MI with an occluded infarct artery.53 Patients with a
clinical suspicion of ongoing myocardial ischaemia and LBBB should be
managed in a way similar to STEMI patients, regardless of whether the
LBBB is previously known. It is important to remark that the presence
of a (presumed) new LBBB does not predict an MI per se.54
Patients with MI and right bundle branch block (RBBB) have a
poor prognosis.55 It may be difficult to detect transmural ischaemia in
patients with chest pain and RBBB.55 Therefore, a primary PCI strat-
egy (emergent coronary angiography and PCI if indicated) should be
considered when persistent ischaemic symptoms occur in the pres-
ence of RBBB.
Recommendations for initial diagnosis
Recommendations Classa Levelb
ECG monitoring
12-lead ECG recording and interpretation is
indicated as soon as possible at the point of
FMC, with a maximum target delay of
10 min.36,38
I B
ECG monitoring with defibrillator capacity
is indicated as soon as possible in all patients
with suspected STEMI.44,45
I B
The use of additional posterior chest wall
leads (V7–V9) in patients with high suspicion
of posterior MI (circumflex occlusion)
should be considered.8,46–49
IIa B
The use of additional right precordial leads
(V3R and V4R) in patients with inferior MI
should be considered to identify concomi-
tant RV infarction.8,43
IIa B
Blood sampling
Routine blood sampling for serum markers
is indicated as soon as possible in the acute
phase but should not delay reperfusion
treatment.8
I C
ECG = electrocardiogram; FMC = first medical contact; MI = myocardial infarc-
tion; RV = right ventricle; STEMI = ST-segment elevation myocardial infarction.
aClass of recommendation.
bLevel of evidence.
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..Ventricular pacing. Pacemaker rhythm may also prevent
interpretation of ST-segment changes and may require urgent angiog-
raphy to confirm diagnosis and initiate therapy. Reprogramming the
pacemaker—allowing an evaluation of ECG changes during intrinsic
heart rhythm—may be considered in patients who are not depend-
ent on ventricular pacing, without delaying invasive investigation.56,57
Non-diagnostic ECG. Some patients with an acute coronary
occlusion may have an initial ECG without ST-segment elevation,
sometimes because they are seen very early after symptom onset (in
which case, one should look for hyper-acute T-waves, which may pre-
cede ST-segment elevation). It is important to repeat the ECG or
monitor for dynamic ST-segment changes. In addition, there is a con-
cern that some patients with acute occlusion of a coronary artery and
ongoing MI, such as those with an occluded circumflex coronary
artery,58,59 acute occlusion of a vein graft, or left main disease, may
present without ST-segment elevation and be denied reperfusion ther-
apy, resulting in a larger infarction and worse outcomes. Extending the
standard 12-lead ECG with V7–V9 leads may identify some of these
patients. In any case, suspicion of ongoing myocardial ischaemia is an
indication for a primary PCI strategy even in patients without diagnos-
tic ST-segment elevation.8,38,46–49 Table 3 lists the atypical ECG pre-
sentations that should prompt a primary PCI strategy in patients with
ongoing symptoms consistent with myocardial ischaemia.
Isolated posterior MI. In AMI of the inferior and basal portion
of the heart, often corresponding to the left circumflex territory, iso-
lated ST-segment depression  0.5 mm in leads V1–V3 represents
the dominant finding. These should be managed as a STEMI. The use
of additional posterior chest wall leads [elevation V7–V9  0.5 mm
(1 mm in men, 40 years old)] is recommended to detect ST-
segment elevation consistent with inferior and basal MI.
Left main coronary obstruction. The presence of ST depres-
sion  1 mm in eight or more surface leads (inferolateral ST depres-
sion), coupled with ST-segment elevation in aVR and/or V1, suggests
multivessel ischemia or left main coronary artery obstruction, partic-
ularly if the patient presents with haemodynamic compromise.60
Blood sampling for serum markers is routinely carried out in the
acute phase. This is indicated, but should not delay the reperfusion
strategy/treatment.
If in doubt regarding the possibility of acute evolving MI, emergency
imaging aids the provision of timely reperfusion therapy to these
patients. Recommendations for the use of echocardiography for ini-
tial diagnosis are described in section 6.6.2. If echocardiography is not
available or if doubts persist after echo, a primary PCI strategy is indi-
cated (including immediate transfer to a PCI centre if the patient is
being treated in a non-PCI centre).
In the STEMI emergency setting, there is no role for routine com-
puted tomography (CT). Use of CT should be confined to selected
cases where acute aortic dissection or pulmonary embolism is sus-
pected, but CT is not recommended if STEMI diagnosis is likely.
Some non-AMI conditions can present with symptoms and ECG
findings similar to STEMI. An emergency coronary angiography is
therefore indicated in these cases (Chapter 9 expands on this topic).
4.2 Relief of pain, breathlessness, and
anxiety
Relief of pain is of paramount importance, not only for comfort rea-
sons but because the pain is associated with sympathetic activation,
which causes vasoconstriction and increases the workload of the
heart. Titrated intravenous (i.v.) opioids (e.g. morphine) are the anal-
gesics most commonly used in this context. However, morphine use
is associated with a slower uptake, delayed onset of action, and
diminished effects of oral antiplatelet agents (i.e. clopidogrel, ticagre-
lor, and prasugrel), which may lead to early treatment failure in sus-
ceptible individuals.61–63
Table 3 Atypical electrocardiographic presentations
that should prompt a primary percutaneous coronary
intervention strategy in patients with ongoing symp-
toms consistent with myocardial ischaemia
ECG = electrocardiogram; LBBB = left bundle branch block; RBBB = right bundle
branch block; RV = right ventricular; STEMI = ST-segment elevation myocardial
infarction.
Relief of hypoxaemia and symptoms
Recommendations Classa Levelb
Hypoxia
Oxygen is indicated in patients with hypo-
xaemia (SaO2 < 90% or PaO2 < 60 mmHg).
I C
Routine oxygen is not recommended in
patients with SaO2  90%.64–66
III B
Symptoms
Titrated i.v. opioids should be considered to
relieve pain.
IIa C
A mild tranquillizer (usually a benzodiaze-
pine) should be considered in very anxious
patients.
IIa C
i.v. = intravenous; PaO2 = partial pressure of oxygen; SaO2 = arterial oxygen
saturation.
aClass of recommendation.
bLevel of evidence.
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..Oxygen is indicated in hypoxic patients with arterial oxygen satu-
ration (SaO2) < 90%. There is some evidence suggesting that hyper-
oxia may be harmful in patients with uncomplicated MI, presumably
due to increased myocardial injury.64–67 Thus, routine oxygen is not
recommended when SaO2 is 90%.
Anxiety is a natural response to the pain and the circumstances
surrounding an MI. Reassurance of patients and those closely associ-
ated with them is of great importance.
A mild tranquillizer (usually a benzodiazepine) should be consid-
ered in anxious patients.
4.3 Cardiac arrest
Many deaths occur very early after STEMI onset due to ventricular
fibrillation (VF).68 As this arrhythmia frequently occurs at an early
stage, these deaths usually happen out of hospital. It is indicated that
all medical and paramedical personnel caring for patients with sus-
pected MI have access to defibrillation equipment and are trained in
cardiac life support, and that, at the point of FMC, ECG monitoring
must be implemented immediately for all patients with suspected MI.
Patients with chest pain suggestive of MI should be directed
through public awareness programmes to contact the EMS and wait
to be transferred to the hospital by the EMS.
In patients following cardiac arrest and ST-segment elevation on
the ECG, primary PCI is the strategy of choice.69–74
Given the high prevalence of coronary occlusions and the potential
difficulties in interpreting the ECG in patients after cardiac arrest,
urgent angiography (within 2 h)2 should be considered in survivors of
cardiac arrest, including unresponsive survivors, when there is a high
index of suspicion of ongoing infarction (such as the presence of
chest pain before arrest, a history of established CAD, and abnormal
or uncertain ECG results).73,74 However, in patients without ST-
segment elevation, a quick evaluation at the emergency department
or intensive cardiac care unit (ICCU) to exclude non-coronary
causes (cerebrovascular event, respiratory failure, non-cardiogenic
shock, pulmonary embolism, and intoxication), and to perform
urgent echocardiography, is reasonable. The decision to perform
urgent coronary angiography and PCI if indicated should also take
into account factors associated with poor neurological outcome.
Unfavourable pre-hospital settings indicating a remote likelihood for
neurological recovery [i.e. unwitnessed cardiac arrest, late arrival of a
pre-hospital team without lay basic life support (>10 min), presence
of an initial non-shockable rhythm, or more than 20 min of advanced
life support without return to spontaneous circulation]75 should be
taken strongly into consideration to argue against an invasive coro-
nary strategy.73
Unconscious patients admitted to critical care units after out-of-
hospital cardiac arrest are at high risk for death, and neurologic defi-
cits are common among those who survive.76 Targeted temperature
management (also called therapeutic hypothermia), aiming for a con-
stant temperature between 32 and 36 C for at least 24 h, is indicated
in patients who remain unconscious after resuscitation from cardiac
arrest (of presumed cardiac cause).73,77–82 However, hypothermia
conditions are associated with slow uptake, delayed onset of action,
and diminished effects of oral antiplatelet agents (i.e. clopidogrel, tica-
grelor, and prasugrel). Moreover, metabolic conversion of clopidog-
rel in the liver may be reduced in hypothermia conditions.83 Cooling
should not delay primary PCI and can be started in parallel in the
catheterization laboratory. Close attention to anticoagulation needs
to be paid in patients reaching low temperatures.84
Prevention and improved treatment of out-of-hospital cardiac
arrest is crucial to reduce the mortality related to CAD. For a more
detailed discussion of these issues, refer to the recent European
Resuscitation Council Guidelines for resuscitation.74
4.4 Pre-hospital logistics of care
4.4.1 Delays
Treatment delays are the most easily audited index of quality of care
in STEMI; they should be recorded in every system providing care to
STEMI patients and be reviewed regularly, to ensure that simple qual-
ity of care indicators are met and maintained over time (see Chapter
Cardiac arrest
Recommendations Classa Levelb
A primary PCI strategy is recommended in
patients with resuscitated cardiac arrest and
an ECG consistent with STEMI.69–71,85
I B
Targeted temperature managementc is indi-
cated early after resuscitation of cardiac
arrest patients who remain
unresponsive.77,78,80–82
I B
It is indicated that healthcare systems imple-
ment strategies to facilitate transfer of all
patients in whom a MI is suspected directly
to the hospital offering 24/7 PCI-mediated
reperfusion therapy via one specialized EMS.
I C
It is indicated that all medical and paramedi-
cal personnel caring for patients with sus-
pected MI have access to defibrillation
equipment and are trained in basic cardiac
life support.
I C
Urgent angiography (and PCI if indicated)
should be considered in patients with resus-
citated cardiac arrest without diagnostic ST-
segment elevation but with a high suspicion
of ongoing myocardial ischaemia.69–71,73
IIa C
Pre-hospital cooling using a rapid infusion of
large volumes of cold i.v. fluid immediately
after return of spontaneous circulation is
not recommended.86
III B
24/7 = 24 h a day, 7 days a week; ECG = electrocardiogram; EMS = emergency
medical system; i.v. = intravenous; MI = myocardial infarction; PCI = percutane-
ous coronary intervention; STEMI = ST-segment elevation myocardial infarction.
aClass of recommendation.
bLevel of evidence.
cTargeted temperature management refers to active methods (i.e. cooling cathe-
ters, cooling blankets, and application of ice applied around the body) to achieve
and maintain a constant specific body temperature between 32 and 36 C in a
person for a specific duration of time (most commonly used  24 h).
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10). If projected target times are not met, then interventions are
needed to improve performance of the system. Components of the
ischaemic time, delays of initial management, and selection of reperfu-
sion strategy are shown in Figure 2.
To minimize patient delay, it is recommended to increase public
awareness of how to recognize common symptoms of AMI and to
call the emergency services. All components of the system delay rep-
resent the quality of care and it is recommended to measure them as
quality indicators (see Chapter 10).
In hospitals and EMS participating in the care of STEMI patients,
the goal is to reduce the delay between FMC and STEMI diagnosis
to <_ 10 min. STEMI diagnosis refers to the time when the ECG is
interpreted as ST-segment elevation or equivalent and it is the time
zero to guide appropriate therapy.
System delay is more readily modifiable by organizational meas-
ures than is patient delay, and it is a predictor of outcomes.87
When STEMI diagnosis is made in the pre-hospital setting (EMS),
immediate activation of the catheterization laboratory not only
reduces treatment delays but may also reduce patient mortality.88–91
When a STEMI diagnosis is made by the EMS in the pre-hospital set-
ting and the patient is triaged for a primary PCI strategy, it is indicated
to bypass the emergency department and bring the patient straight
Figure 2 Modes of patient presentation, components of ischaemia time and flowchart for reperfusion strategy selection. EMS = Emergency
Medical System; FMC = First Medical Contact; PCI = Percutaneous Coronary Intervention; STEMI = ST-segment elevation myocardial infarction.
The recommended mode of patient presentation is by alerting the EMS (call national emergency number: 112 or similar number
according to region). When STEMI diagnosis is made in the out-of-hospital setting (via EMS) or in a non-PCI centre, the decision for
choosing reperfusion strategy is based on the estimated time from STEMI diagnosis to PCI-mediated reperfusion (wire crossing).
System delay for patients alerting the EMS starts at the time of phone alert, although FMC occurs when EMS arrives to the scene (see
Table 4).denotes minutes. aPatients with fibrinolysis should be transferred to a PCI centre immediately after administration of the lytic
bolus.
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..to the catheterization laboratory. Bypassing the emergency depart-
ment is associated with a 20 min saving in the time from FMC to wire
crossing.92 For patients presenting in a non-PCI centre, door-in to
door-out time, defined as the duration between arrival of the patient
at the hospital to discharge of the patient in an ambulance en route
to the PCI centre, is a new clinical performance measure, and
<_30 min is recommended to expedite reperfusion care.93
4.4.2 Emergency medical system
An EMS with an easily recalled and well publicized unique medical dis-
patching number (112 for most medical emergencies across Europe)
is important to speed up activation. Parallel circuits for referral and
transport of patients with a STEMI that bypass the EMS should be
avoided. The ambulance system has a critical role in the early man-
agement of STEMI patients and it is not only a mode of transport but
also a system to enhance early initial diagnosis, triage, and
treatment.87,94
It is indicated that all ambulances in the EMS are equipped with
ECG recorders, defibrillators, and at least one person trained in
advanced life support. The quality of the care provided depends
on the training of the staff involved. It is indicated that all ambulance
personnel are trained to recognize the symptoms of an AMI, adminis-
ter oxygen when appropriate, relieve pain, and provide basic life sup-
port.95 Ambulance staff should be able to record an ECG for
diagnostic purposes and either interpret or transmit it, so that it can
be reviewed by experienced staff in a coronary care unit (CCU)/
ICCU or elsewhere and establish a STEMI diagnosis. Paramedics
trained to administer fibrinolytics do so safely and effectively.96 As
pre-hospital fibrinolysis is indicated in patients presenting early when
anticipated STEMI diagnosis to PCI-mediated reperfusion time
is > 120 min,97–99 ongoing training of paramedics to undertake
these functions is recommended, even in the current setting of pri-
mary PCI.
4.4.3 Organization of ST-segment elevation myocardial
infarction treatment in networks
Optimal treatment of STEMI should be based on the implementation
of networks between hospitals (‘hub’ and ‘spoke’) with various levels
of technology, linked by a prioritized and efficient ambulance service.
The goal of these networks is to provide optimal care while minimiz-
ing delays, thereby improving clinical outcomes. Cardiologists should
actively collaborate with all stakeholders, particularly emergency
physicians, in establishing such networks. The main features of such a
network are:
 Clear definition of geographic areas of responsibility.
 Shared written protocols, based on risk stratification and transportation
by a trained physician, nurse, or paramedic staff in appropriately
equipped ambulances or helicopters.
 Pre-hospital triage of STEMI patients to the appropriate institution,
bypassing non-PCI hospitals or hospitals without a 24 h a day, 7 days a
week (24/7) primary PCI programme.
 On arrival at the appropriate hospital, the patient should immediately
be taken to the catheterization laboratory, bypassing the emergency
department.
 Patients presenting to a non-PCI-capable hospital and awaiting trans-
portation for primary or rescue PCI must be attended in an appropri-
ately monitored and staffed area.
 If the diagnosis of STEMI has not been made by the ambulance crew
and the ambulance arrives at a non-PCI-capable hospital, the ambu-
lance should await the diagnosis and, if a STEMI diagnosis is made,
should continue to a PCI-capable hospital.
To maximize staff experience, primary PCI centres should perform
the procedure systematically on a 24/7 basis for all STEMI patients.
Other models, although not ideal, may include weekly or daily rotation
of primary PCI centres or multiple primary PCI centres in the same
region. Hospitals that cannot offer a 24/7 service for primary PCI
should be allowed to perform primary PCI in patients already admit-
ted for another reason who develop STEMI during their hospital stay.
However, these hospitals should be discouraged from initiating a serv-
ice limited to daytime- or within-hours primary PCI, as this may gener-
ate confusion with the EMS operators and may affect the STEMI
diagnosis-to-reperfusion time and the quality of intervention of
focused 24/7 true primary PCI centres. Therefore, it is indicated that
the EMS transports STEMI patients to hospitals with an established
interventional cardiology programme available 24/7, if necessary
bypassing a non-PCI-capable hospital (if the transfer time is within the
recommended time-windows for primary PCI; see Figure 3).
Geographic areas where the expected transfer time to the primary
PCI centre makes it impossible to achieve the maximal allowable
delays indicated in the recommendations (Figure 2) should develop
systems for rapid fibrinolysis, at the place of STEMI diagnosis, with
subsequent immediate transfer to primary PCI centres. Such net-
works increase the proportion of patients receiving reperfusion with
the shortest possible treatment delay.100–102 The quality of care,
time delays, and patient outcomes should be measured and com-
pared at regular intervals for improvement.
4.4.3.1. General practitioners
In some countries, general practitioners play a role in the early care
of patients with AMI and are often the first to be contacted by the
patients.
If general practitioners respond quickly they can be very effective,
as they usually know the patient and can perform and interpret the
ECG. Their first task after the STEMI diagnosis should be to alert the
EMS. In addition, they can administer opioids and antithrombotic
drugs (including fibrinolytics, if that management strategy is indi-
cated), and can undertake defibrillation if needed. However, in most
settings, consultation with a general practitioner—instead of a direct
call to the EMS—will increase pre-hospital delay. Therefore, in gen-
eral, the public should be educated to call the EMS rather than the
primary care physician for symptoms suggestive of MI.
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.. 5. Reperfusion therapy
5.1 Selection of reperfusion strategies
Table 4 lists the definitions of terms relating to reperfusion therapy.
Primary PCI is the preferred reperfusion strategy in patients with
STEMI within 12 h of symptom onset, provided it can be performed
expeditiously (i.e. 120 min from STEMI diagnosis, Figures 2 and 3) by
an experienced team. An experienced team includes not only inter-
ventional cardiologists but also skilled support staff. Lower mortality
rates among patients undergoing primary PCI are observed in centres
with a high volume of PCI procedures.111 Real-life data confirm that
primary PCI is performed faster and results in lower mortality if per-
formed in high-volume centres.112 Randomized clinical trials in high-
volume, experienced centres have repeatedly shown that, if delay to
treatment is similar, primary PCI is superior to fibrinolysis in reducing
mortality, reinfarction, or stroke.113–116 However, in some circum-
stances, primary PCI is not an immediate option and fibrinolysis could
be initiated expeditiously. The extent to which the PCI-related time
delay diminishes the advantages of PCI over fibrinolysis has been
widely debated. Because no specifically designed study has addressed
Logistics of pre-hospital care
Recommendations Classa Levelb
It is recommended that the pre-hospital
management of STEMI patients is based on
regional networks designed to deliver
reperfusion therapy expeditiously and effec-
tively, with efforts made to make primary
PCI available to as many patients as
possible.100
I B
It is recommended that primary PCI-capable
centres deliver a 24/7 service and are able
to perform primary PCI without
delay.18,103,104
I B
It is recommended that patients transferred
to a PCI-capable centre for primary PCI
bypass the emergency department and
CCU/ICCU and are transferred directly to
the catheterization laboratory.92,107–110
I B
It is recommended that ambulance teams
are trained and equipped to identify STEMI
(with use of ECG recorders and telemetry
as necessary) and administer initial therapy,
including fibrinolysis when applicable.95
I C
It is recommended that all hospitals and
EMS participating in the care of patients
with STEMI record and audit delay times
and work to achieve and maintain quality
targets.105–107
I C
It is recommended that EMS transfer STEMI
patients to a PCI-capable centre, bypassing
non-PCI centres.
I C
It is recommended that EMS, emergency
departments, and CCU/ICCU have a writ-
ten updated STEMI management protocol,
preferably shared within geographic
networks.
I C
It is recommended that patients presenting
to a non-PCI-capable hospital and awaiting
transportation for primary or rescue PCI
are attended in an appropriately monitored
area (e.g. the emergency department, CCU/
ICCU, or intermediate care unit).
I C
24/7 = 24 h a day, 7 days a week; CCU = coronary care unit; ECG = electrocar-
diogram; EMS = emergency medical system; ICCU = intensive cardiac care unit;
PCI = percutaneous coronary intervention; STEMI = ST-segment elevation myo-
cardial infarction.
aClass of recommendation.
bLevel of evidence.
Table 4 Definitions of terms related to reperfusion
therapy
ECG = electrocardiogram; EMS = emergency medical system; FMC = first medi-
cal contact; IRA = infarct-related artery; PCI = percutaneous coronary interven-
tion; STEMI = ST-segment elevation myocardial infarction.
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this issue, caution is needed when interpreting available data from
post hoc analyses. A PCI-related time delay potentially mitigating the
benefits of PCI has been calculated as 60 min117, 110 min,118 and
120 min119 in different studies. Registry data estimated this time limit
as 114 min for in-hospital patients107 and 120 min in patients present-
ing in a non-PCI centre.120 All these data are old and patients under-
going fibrinolysis did not undergo routine early angiography, which
improves outcomes in patients receiving fibrinolysis. The recent
STrategic Reperfusion Early After Myocardial infarction (STREAM)
trial randomized early STEMI presenters without the possibility of
immediate PCI to immediate fibrinolysis (followed by routine early
angiography) or transfer to primary PCI.121 The median PCI-related
delay in this trial was 78 min, and there were no differences in clinical
outcomes. This Task Force recognizes the lack of contemporaneous
data to set the limit to choose PCI over fibrinolysis. For simplicity, an
absolute time from STEMI diagnosis to PCI-mediated reperfusion [i.e.
wire crossing of the infarct-related artery (IRA)] rather than a relative
PCI-related delay over fibrinolysis has been chosen. This limit is set to
Figure 3 Maximum target times according to reperfusion strategy selection in patients presenting via EMS or in a non-PCI centre. ECG = electro-
cardiogram; PCI = Percutaneous Coronary Intervention; STEMI = ST-segment elevation myocardial infarction. STEMI diagnosis is the time 0 for the
strategy clock. The decision for choosing reperfusion strategy in patients presenting via EMS (out-of-hospital setting) or in a non-PCI centre is based
on the estimated time from STEMI diagnosis to PCI-mediated reperfusion. Target times from STEMI diagnosis represent the maximum time to do
specific interventions.
aif fibrinolysis is contra-indicated, direct for primary PCI strategy regardless of time to PCI.
b10 min is the maximum target delay time from STEMI diagnosis to fibrinolytic bolus administration, however, it should be given as
soon as possible after STEMI diagnosis (after ruling out contra-indications).
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120 min. Given the maximum limit of 10 min from STEMI diagnosis to
bolus of fibrinolytics (see below), the 120 min absolute time would
correspond to a PCI-related delay in the range of 110–120 min, being
in the range of the times identified in old studies and registries as the
limit delay to choose PCI.107,117–120
If the reperfusion strategy is fibrinolysis, the goal is to inject the
bolus of fibrinolytics within 10 min from STEMI diagnosis. This time is
selected based on the median time from randomization to bolus
recorded in the STREAM trial, which was 9 min.121 In previous ESC
STEMI guidelines,122 the target time was 30 min, but this was calcu-
lated from FMC (as opposed to STEMI diagnosis). STEMI diagnosis
should occur within 10 min from FMC.
Figure 3 summarizes target times for patients presenting in the pre-
hospital setting or in a non-PCI centre.
To shorten time to treatment, fibrinolysis should be administered
in the pre-hospital setting if possible98,121,123 (Figures 2 and 3).
Patients should be transferred to a PCI-capable facility as soon as pos-
sible after bolus of lytics administration. Rescue PCI is indicated in the
case of failed fibrinolysis (i.e. ST-segment resolution < 50% within
60–90 min of fibrinolytic administration), or in the presence of hae-
modynamic or electrical instability, worsening ischaemia, or persis-
tent chest pain,121,124 while a routine early PCI strategy is indicated
after successful fibrinolysis (preferably 2–24 h after fibrinolysis) (see
section 5.3).125–130
Patients with a clinical presentation compatible with AMI and a
non-interpretable ST-segment on the ECG, such as those with bun-
dle branch block or ventricular pacing,55,131,132 should undergo a pri-
mary PCI strategy.
There is general agreement that a primary PCI strategy should also
be followed for patients with symptoms lasting >12 h in the presence
of: (1) ECG evidence of ongoing ischaemia; (2) ongoing or recurrent
pain and dynamic ECG changes; and (3) ongoing or recurrent pain,
symptoms, and signs of heart failure, shock, or malignant arrhythmias.
However, there is no consensus as to whether PCI is also beneficial
in patients presenting >12 h from symptom onset in the absence of
clinical and/or electrocardiographic evidence of ongoing ischaemia. In
asymptomatic patients without persistent symptoms 12–48 h after
symptom onset, a small (n = 347) randomized study showed
improved myocardial salvage and 4 year survival in patients treated
with primary PCI compared with conservative treatment alone.133,134
However, in stable patients with persistent occlusion of the IRA
3–28 days after MI, the large (n = 2166) Occluded Artery Trial
(OAT) revealed no clinical benefit from routine coronary interven-
tion with medical management, beyond that from medical manage-
ment alone.135,136 A meta-analysis of trials testing whether late
recanalization of an occluded IRA is beneficial showed no benefit of
reperfusion.137 Therefore, routine PCI of an occluded IRA in asymp-
tomatic patients >48 h after onset of symptoms is not indicated.
These patients should be managed like all patients with chronic total
occlusion, in which revascularization should be considered in the
presence of symptoms or objective evidence of viability/ischaemia in
the territory of the occluded artery.1
Recommendations for reperfusion therapy
Recommendation Classa Levelb
Reperfusion therapy is indicated in all
patients with symptoms of ischaemia
of <_ 12 h duration and persistent ST-seg-
ment elevation.119,138
I A
A primary PCI strategy is recommended
over fibrinolysis within indicated
timeframes.114,116,139,140
I A
If timely primary PCI cannot be performed
after STEMI diagnosis, fibrinolytic therapy is
recommended within 12 h of symptom
onset in patients without
contraindications.107,120,122
I A
In the absence of ST-segment elevation, a
primary PCI strategy is indicated in patients
with suspected ongoing ischaemic symp-
toms suggestive of MI and at least one of
the following criteria present:
- haemodynamic instability or cardiogenic
shock
- recurrent or ongoing chest pain refrac-
tory to medical treatment
- life-threatening arrhythmias or cardiac
arrest
- mechanical complications of MI
- acute heart failure
- recurrent dynamic ST-segment or T-
wave changes, particularly with intermit-
tent ST-segment elevation.
I C
Early angiography (within 24 h) is recom-
mended if symptoms are completely
relieved and ST-segment elevation is com-
pletely normalized spontaneously or after
nitroglycerin administration (provided there
is no recurrence of symptoms or ST-seg-
ment elevation).
I C
In patients with time from symptom onset
>12 h, a primary PCI strategy is indicated in
the presence of ongoing symptoms sugges-
tive of ischaemia, haemodynamic instability,
or life-threatening arrhythmias.141
I C
A routine primary PCI strategy should be
considered in patients presenting late
(12–48 h) after symptom onset.133,134,142
IIa B
In asymptomatic patients, routine PCI of an
occluded IRA >48 h after onset of STEMI is
not indicated.135,137
III A
IRA = infarct-related artery; MI, myocardial infarction; PCI = percutaneous coro-
nary intervention; STEMI = ST-segment elevation myocardial infarction.
aClass of recommendation.
bLevel of evidence.
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Table 5 summarizes the important time targets in acute STEMI.
5.2 Primary percutaneous coronary
intervention and adjunctive therapy
5.2.1 Procedural aspects of primary percutaneous
coronary intervention
5.2.1.1 Access route
Over recent years, several studies have provided robust evidence in
favour of the radial approach as the default access site in ACS patients
undergoing primary PCI by experienced radial operators. The
Minimizing Adverse Haemorrhagic Events by TRansradial Access Site
and Systemic Implementation of angioX (MATRIX)143 trial recruited
8404 ACS patients (48% STEMI) who were randomly allocated to
transradial or transfemoral access. Radial access was associated with
lower risks of access site bleeding, vascular complications, and need
for transfusion. Importantly, there was a significant mortality benefit
in patients allocated to the transradial access site, which reinforced
previous observations from the Radial Versus Femoral Access for
Coronary Intervention (RIVAL) access for coronary intervention
trial,144 and the Radial Versus Femoral Randomized Investigation in
ST-Elevation Acute Coronary Syndrome (RIFLE-STEACS) trial.145
No significant interaction was observed in the MATRIX trial between
the type of ACS and treatment benefit, suggesting that the results of
this investigation can be extended with confidence to the treatment
of patients with STEMI.
5.2.1.2 Stenting in primary percutaneous intervention
Coronary stenting is the technique of choice during primary PCI.
Compared with balloon angioplasty alone, stenting with a bare-metal
stent (BMS) is associated with a lower risk of reinfarction and target
vessel revascularization but is not associated with a reduction in the
mortality rate.146,147 In primary PCI, drug-eluting stents (DES) reduce
the risk of repeated target vessel revascularization compared with
BMS.148
New-generation DES have shown superior safety and preserved
or even improved efficacy compared with first-generation DES, in
particular with respect to lower risks of stent thrombosis and recur-
rent MI. In two recent trials—the Effect of biolimus-eluting stents
with biodegradable polymer vs. bare-metal stents on cardiovascular
events among patients with AMI (COMFORTABLE AMI) trial149 and
the Everolimus-Eluting Stents Versus Bare-Metal Stents in ST-
Segment Elevation Myocardial Infarction (EXAMINATION)
trial150—new-generation DES have been shown to be superior to
BMS in patients with AMI, mostly in terms of need for reintervention.
In the latter trial, the recently released 5 year follow-up results
showed a reduction in all-cause mortality by DES as compared to
BMS.151 In the Norwegian Coronary Stent (NORSTENT) trial,152
9013 patients undergoing PCI (26% with STEMI) were randomized
to DES or BMS. There were no differences in the incidence of the pri-
mary endpoint (composite of death from any cause or non-fatal
spontaneous MI) after a median follow-up of 5 years. However, DES
were associated with lower rates of definite stent thrombosis (0.8%
vs. 1.2%; P = 0.0498) and of target lesion and any repeat revasculariza-
tion (16.5% vs. 19.8%; P < 0.001).152
Deferring stenting in primary PCI has been investigated as an
option to reduce microvascular obstruction (MVO) and preserve
microcirculatory function. Two small studies recently found opposite
results in the effect of deferred stenting on cardiac magnetic reso-
nance (CMR) imaging-measured MVO.153,154 In the larger DANish
Study of Optimal Acute Treatment of Patients with ST-segment
Elevation Myocardial Infarction – Deferred versus conventional stent
implantation in patients with ST-segment elevation myocardial infarc-
tion (DANAMI 3-DEFER) trial,155 in 1215 STEMI patients, deferred
stenting (48 h after the index procedure) had no effect on the pri-
mary clinical outcome (composite of all-cause mortality, non-fatal MI,
or ischaemia-driven revascularization of non-IRA lesions). Routine
deferred stenting was associated with a higher need for target vessel
revascularization. Based on these findings, routine use of deferred
stenting is not recommended.
5.2.1.3 Thrombus aspiration
A number of small-scale or single-centre studies and one meta-analysis
of 11 small trials156 suggested that there could be benefits from routine
manual thrombus aspiration during primary PCI. Recently, two large
(>10 000 and >7000 patients) randomized controlled trials, which
were adequately powered to detect superiority of routine manual
thrombus aspiration versus conventional PCI, showed no benefit on
clinical outcomes of routine aspiration strategy overall.157–160 A safety
concern emerged in the Trial of Routine Aspiration Thrombectomy
with PCI versus PCI Alone in Patients with STEMI (TOTAL) trial (n =
10 732), with an increase in the risk of stroke.161 In the subgroup with
high thrombus burden [TIMI (Thrombolysis in Myocardial Infarction)
thrombus grade  3], thrombus aspiration was associated with fewer
cardiovascular deaths [170 (2.5%) vs. 205 (3.1%); hazard ratio (HR)
0.80, 95% confidence interval (CI) 0.65–0.98; P = 0.03] and with more
strokes or transient ischaemic attacks [55 (0.9%) vs. 34 (0.5%); odds
Table 5 Summary of important time targets
ECG = electrocardiogram; FMC = first medical contact; PCI = percutaneous cor-
onary intervention; STEMI = ST-segment elevation myocardial infarction
aECG should be interpreted immediately.
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ratio 1.56, 95% CI 1.02–2.42, P =0.04]. However, the interaction P val-
ues were 0.32 and 0.34, respectively.162
In the Taste157 and TOTAL trials159, 1–5% of randomized patients
crossed over from PCI alone to thrombus aspiration. Based on these
data and the results of a recent meta-analysis,162 routine thrombus
aspiration is not recommended, but in cases of large residual throm-
bus burden after opening the vessel with a guide wire or a balloon,
thrombus aspiration may be considered.
5.2.1.4 Multivessel coronary revascularization
Multivessel disease is common (in approximately 50%) in patients
with STEMI.163,164 While it is recommended to always treat the IRA,
evidence supporting immediate (preventive) revascularization of
additional significant coronary stenoses is conflicting. It has been
reported that patients with extensive CAD in vessels remote from
the IRA have lower rates of ST-segment recovery and an adverse
prognosis following primary PCI.163 Data from the US National
Cardiovascular Data Registry and New York State’s Percutaneous
Coronary Interventions Reporting System suggested an increase in
adverse events, including mortality, in patients treated with immedi-
ate multivessel revascularization versus IRA PCI only, while patients
in cardiogenic shock were excluded from the analysis.165,166
Randomized clinical trials addressing this issue have been small (each
of them included from 69 to 885 patients). One study allocated 214
STEMI patients with multivessel disease to three arms: IRA angioplasty-
only, simultaneous treatment of non-IRA lesions, and staged revascula-
rization of the non-IRA. At a mean follow-up of 2.5 years, patients allo-
cated to IRA angioplasty-only had more major adverse cardiac events
(MACE) (i.e. death, reinfarction, rehospitalization for ACS, and repeat
coronary revascularization) than the patients treated with other strat-
egies.167 After this study, four randomized clinical trials have compared
PCI of the IRA only vs. complete revascularization: the Preventive
Angioplasty in Acute Myocardial Infarction (PRAMI) trial (n = 465,
23 months follow-up),168 the Complete Versus Lesion-Only Primary
PCI Trial (CvLPRIT) (n = 296, 12 months follow-up),169 the Complete
revascularisation versus treatment of the culprit lesion only in patients
with ST-segment elevation myocardial infarction and multivessel dis-
ease (DANAMI-3–PRIMULTI) trial (n = 627, 27 months follow-up),170
and the Comparison Between FFR Guided Revascularization Versus
Conventional Strategy in Acute STEMI Patients With Multivessel dis-
ease (Compare-Acute, n = 885, 12 months follow-up) trial.171 PCI of
non-IRA was done either during the index procedure (PRAMI and
Compare-Acute), staged during hospital admission (DANAMI-
3–PRIMULTI), or any time before discharge (immediate or staged)
(CVLPRIT). Indication for PCI in non-IRA was angiography-guided in
lesions with 50% stenosis (PRAMI), >70% stenosis (CVLPRIT), or
fractional flow reserve (FFR)-guided (DANAMI-3–PRIMULTI and
Compare-Acute). Primary outcome (composite of different end-
points) was significantly reduced in the complete revascularization
group in all four trials. Total mortality was not statistically different in
any of the four trials. Repeat revascularization was significantly reduced
in the complete revascularization arm in the PRAMI, DANAMI-
3–PRIMULTI, and Compare-Acute trials. Non-fatal MI was reduced in
the non-IRA PCI group only in PRAMI. The lack of significant treatment
effect of non-IRA lesion intervention on death or MI was confirmed by
three meta-analyses172–174 (none of these meta-analyses included
the Compare-Acute trial, and one173 did not include the
DANAMI-3–PRIMULTI). Based on these data, revascularization of
non-IRA lesions should be considered in STEMI patients with multives-
sel disease before hospital discharge. As the optimal timing of revascu-
larization (immediate vs. staged) has not been adequately investigated,
no recommendation in favour of immediate vs. staged multivessel PCI
can be formulated.
5.2.1.5 Intra-aortic balloon pump
The Counterpulsation to Reduce Infarct Size Pre-PCI-Acute Myocar-
dial Infarction (CRISP AMI) trial showed no benefit from a routine
intra-aortic balloon pump (IABP) in anterior MI without shock,175 but
there was increased bleeding, which is consistent with previous data
regarding the role of IABP in high-risk STEMI without cardiogenic
shock.176 In addition, a recent randomized trial showed that IABP did
not improve outcomes in MI with cardiogenic shock.177 Haemody-
namic support in patients with cardiogenic shock is discussed in
Chapter 8.
Procedural aspects of the primary percutaneous cor-
onary intervention strategy
Recommendations Classa Levelb
IRA strategy
Primary PCI of the IRA is indicated.114,116,139,140 I A
New coronary angiography with PCI if indicated is
recommended in patients with symptoms or signs
of recurrent or remaining ischaemia after primary
PCI.
I C
IRA technique
Stenting is recommended (over balloon angio-
plasty) for primary PCI.146,147
I A
Stenting with new-generation DES is recom-
mended over BMS for primary PCI.148–151,178,179
I A
Radial access is recommended over femoral
access if performed by an experienced radial
operator.143–145,180
I A
Routine use of thrombus aspiration is not
recommended.157,159
III A
Routine use of deferred stenting is not
recommended.153–155
III B
Non-IRA strategy
Routine revascularization of non-IRA lesions
should be considered in STEMI patients with mul-
tivessel disease before hospital discharge.167–173
IIa A
Non-IRA PCI during the index procedure should
be considered in patients with cardiogenic shock.
IIa C
CABG should be considered in patients with
ongoing ischaemia and large areas of jeopardized
myocardium if PCI of the IRA cannot be performed.
IIa C
CABG = coronary artery bypass graft surgery; DES = drug-eluting stent; IRA =
infarct-related artery; PCI = percutaneous coronary intervention; STEMI = ST-
segment elevation myocardial infarction.
aClass of recommendation.
bLevel of evidence.
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..5.2.2 Periprocedural pharmacotherapy
5.2.2.1 Platelet inhibition
Patients undergoing primary PCI should receive DAPT, a combina-
tion of aspirin and a P2Y12 inhibitor, and a parenteral anticoagulant.
Aspirin can be given orally including chewing, or i.v. to ensure com-
plete inhibition of thromboxane A2-dependent platelet aggregation.
The oral dose of plain aspirin (non-enteric-coated formulation)
should preferably be 150–300 mg. There are few clinical data on the
optimal i.v. dosage. Given a 50% oral bioavailability of oral aspirin, a
corresponding dose is 75–150 mg. Pharmacological data suggest that
this lower dose range avoids inhibition of cyclooxygenase-2-
dependent prostacyclin. A recent randomized study showed that a
single dose of 250 or 500 mg acetylsalicylic acid i.v. compared to
300 mg orally was associated with a faster and more complete inhibi-
tion of thromboxane generation and platelet aggregation at 5 min,
with comparable rates of bleeding complications.181
There is limited evidence with respect to when the P2Y12 inhibitor
should be initiated in STEMI patients. The Administration of
Ticagrelor in the Cath Lab or in the Ambulance for New ST Elevation
Myocardial Infarction to Open the Coronary Artery (ATLANTIC)
trial182 is the only randomized study testing the safety and efficacy of
different timings of P2Y12 inhibitor initiation in STEMI. In this trial,
patients were randomized to receive ticagrelor either during transfer
to a primary PCI centre or immediately before angiography.182 The
median difference between the two tested loading treatment strat-
egies was only 31 min. This study failed to meet the pre-specified pri-
mary endpoint in terms of improved ST-segment elevation
resolution or TIMI flow before intervention. Rates of major and
minor bleeding events were identical in both treatment arms. While
the evidence of a clinical benefit of P2Y12 inhibitor pre-treatment in
this setting is lacking, early initiation of a P2Y12 inhibitor while the
patient is being transported to a primary PCI centre is common prac-
tice in Europe and is consistent with the pharmacokinetic data.
Furthermore, early treatment with high-dose clopidogrel was supe-
rior to in-catheterization laboratory treatment in observational stud-
ies and one small randomized trial.183–185 In all, the data suggest that
the earliest administration may be preferable to achieve early efficacy,
particularly for long delays. However, in cases in which the STEMI
diagnosis is not clear, delaying P2Y12 inhibitor loading until the anat-
omy is known should be considered.
The preferred P2Y12 inhibitors are prasugrel [60 mg loading dose
and 10 mg maintenance dose once daily per os (p.o.)] or ticagrelor
(180 mg p.o. loading dose and 90 mg maintenance dose twice daily).
These drugs have a more rapid onset of action, greater potency, and
are superior to clopidogrel in clinical outcomes.186,187 Prasugrel is
contraindicated in patients with previous stroke/transient ischaemic
attack, and its use is generally not recommended in patients aged
75 years or in patients with lower body weight (<60 kg) as it was
not associated with net clinical benefit in these subsets. In case prasu-
grel is used in these patients, a reduced dose (5 mg)188 is recom-
mended. Ticagrelor may cause transient dyspnoea at the onset of
therapy, which is not associated with morphological or functional
lung abnormalities, and which rarely leads to permanent discontinua-
tion.189 Neither prasugrel nor ticagrelor should be used in patients
with a previous haemorrhagic stroke, in patients on oral anticoagu-
lants, or in patients with moderate-to-severe liver disease.
When neither of these agents is available (or if they are contraindi-
cated), clopidogrel 600 mg p.o. should be given instead.190
Clopidogrel has not been evaluated against placebo in any large out-
comes studies in the setting of primary PCI, but a higher regimen of a
600 mg loading dose/150 mg maintenance dose in the first week was
superior to the 300/75 mg regimen in the subset of patients under-
going PCI in the Clopidogrel and aspirin Optimal Dose usage to
reduce recurrent events–Seventh organization to assess strategies in
ischaemic syndromes (CURRENT-OASIS 7) trial,190 and use of high
clopidogrel loading doses has been demonstrated to achieve more
rapid inhibition of the adenosine diphosphate receptor. All P2Y12
inhibitors should be used with caution in patients at high risk of bleed-
ing or with significant anaemia.
Cangrelor is a potent i.v. reversible P2Y12 inhibitor with a rapid
onset and offset of action. It has been assessed in three random-
ized controlled trials enrolling patients with PCI for stable angina
or ACS against clopidogrel loading or placebo.191–193 A pooled
analysis of these three trials showed that cangrelor reduced peri-
procedural ischaemic complications at the expense of an increased
risk of bleeding.194 The fact that no potent P2Y12 inhibitors (prasu-
grel or ticagrelor) were used in patients with an ACS, and only
about 18% of the enrolled patients presented with STEMI,193 limits
the applicability of the results to current practice of management
of STEMI patients. Nevertheless, cangrelor may be considered in
patients not pre-treated with oral P2Y12 receptor inhibitors at the
time of PCI or in those who are considered unable to absorb oral
agents.
The pre-hospital routine upstream use of glycoprotein (GP) IIb/IIIa
inhibitors before primary PCI has not been demonstrated to offer a
benefit and increases bleeding risk compared with routine use in the
catheterization laboratory.195,196 Procedural use of abciximab plus
unfractionated heparin (UFH) showed no benefit compared to biva-
lirudin.197 Using GP IIb/IIIa inhibitors as bailout therapy in the event of
angiographic evidence of a large thrombus, slow- or no-reflow, and
other thrombotic complications is reasonable, although this strategy
has not been tested in a randomized trial. Overall, there is no evi-
dence to recommend the routine use of GP IIb/IIIa inhibitors for pri-
mary PCI. The intracoronary administration of GP IIb/IIIa inhibitors is
not superior to its i.v. use.198
5.2.2.2 Anticoagulation
Anticoagulant options for primary PCI include UFH, enoxaparin, and
bivalirudin. Use of fondaparinux in the context of primary PCI was
associated with potential harm in the Organization for the
Assessment of Strategies for Ischemic Syndromes 6 (OASIS 6) trial
and is not recommended.199
There has been no placebo-controlled trial evaluating UFH in pri-
mary PCI, but there is a large body of experience with this agent.
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Dosage should follow standard recommendations for PCI (i.e. initial
bolus 70–100 U/kg). There are no robust data recommending the
use of activated clotting time to tailor dose or monitor UFH, and if
activated clotting time is used, it should not delay recanalization of
the IRA. An i.v. bolus of enoxaparin 0.5 mg/kg was compared with
UFH in the randomized open-label Acute myocardial infarction
Treated with primary angioplasty and inTravenous enOxaparin or
unfractionated heparin to Lower ischaemic and bleeding events at
short- and Long-term follow-up (ATOLL) trial, including 910 STEMI
patients.200 The primary composite endpoint of 30 day death, MI,
procedural failure, or major bleeding was not significantly reduced by
enoxaparin (17% relative risk reduction, P = 0.063), but there was a
reduction in the composite main secondary endpoint of death, recur-
rent MI or ACS, or urgent revascularization. Importantly, there was
no evidence of increased bleeding following the use of enoxaparin
over UFH.200 In the per-protocol analysis of the ATOLL trial (87% of
the study population), i.v. enoxaparin was superior to UFH in reduc-
ing the primary endpoint, ischaemic endpoints, mortality, and major
bleeding.201 In a meta-analysis of 23 PCI trials (30 966 patients, 33%
primary PCI), enoxaparin was associated with a significant reduction
in death compared to UHF. This effect was particularly significant in
the primary PCI context and was associated with a reduction in major
bleeding.202 Based on these considerations, enoxaparin should be
considered in STEMI.
Five dedicated randomized controlled trials have compared bivalir-
udin with UFH with or without planned use of GP IIb/IIIa inhibitors in
patients with STEMI.197,203–207 A meta-analysis of these trials showed
no mortality advantage with bivalirudin and a reduction in the risk of
major bleeding, but at the cost of an increased risk of acute stent
thrombosis.208 In the recent MATRIX trial including 7213 ACS
patients (56% with STEMI), bivalirudin did not reduce the incidence
of the primary endpoint (composite of death, MI, or stroke) com-
pared to UFH. Bivalirudin was associated with lower total and cardio-
vascular mortality, lower bleeding, and more definite stent
thrombosis.209 The recently published STEMI subanalysis confirmed
a lack of statistical interaction between the type of ACS and out-
comes within the study.210 The MATRIX trial showed that prolonging
bivalirudin infusion after PCI did not improve the outcomes com-
pared with bivalirudin infusion confined to the duration of PCI.209
However, a post hoc analysis suggested that prolonging bivalirudin
with a full-PCI dose after PCI was associated with the lowest risk of
ischaemic and bleeding events, which is in accordance with the cur-
rent label of the drug.209 Based on these data, bivalirudin should be
considered in STEMI, especially in patients at high bleeding
risk.197,211,212 Bivalirudin is recommended for patients with heparin-
induced thrombocytopenia.
Routine post-procedural anticoagulant therapy is not indicated
after primary PCI, except when there is a separate indication for
either full-dose anticoagulation [due, for instance, to atrial fibrillation
(AF), mechanical valves, or LV thrombus)2 or prophylactic doses for
the prevention of venous thromboembolism in patients requiring
prolonged bed rest.
Periprocedural and post-procedural antithrombotic
therapya in patients undergoing primary percutaneous
coronary intervention
Recommendations Classb Levelc
Antiplatelet therapy
A potent P2Y12 inhibitor (prasugrel or tica-
grelor), or clopidogrel if these are not avail-
able or are contraindicated, is
recommended before (or at latest at the
time of) PCI and maintained over
12 months, unless there are contraindica-
tions such as excessive risk of
bleeding.186,187
I A
Aspirin (oral or i.v. if unable to swallow) is
recommended as soon as possible for all
patients without contraindications.213,214
I B
GP IIb/IIIa inhibitors should be considered
for bailout if there is evidence of no-reflow
or a thrombotic complication.
IIa C
Cangrelor may be considered in patients
who have not received P2Y12 receptor
inhibitors.192–194
IIb A
Anticoagulant therapy
Anticoagulation is recommended for all
patients in addition to antiplatelet therapy
during primary PCI.
I C
Routine use of UFH is recommended. I C
In patients with heparin-induced thrombo-
cytopenia, bivalirudin is recommended as
the anticoagulant agent during primary PCI.
I C
Routine use of enoxaparin i.v. should be
considered.200–202
IIa A
Routine use of bivalirudin should be
considered.209,215
IIa A
Fondaparinux is not recommended for pri-
mary PCI.199 III B
GP = glycoprotein; i.v. = intravenous; PCI = percutaneous coronary intervention;
UFH = unfractionated heparin.
aDose regimens are specified in Table 6.
bClass of recommendation.
cLevel of evidence.
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5.2.2.3 Therapies to reduce infarct size and microvascular obstruction
Final infarct size and MVO are major independent predictors of
long-term mortality and heart failure in survivors of STEMI.216,217
MVO is defined as inadequate myocardial perfusion after success-
ful mechanical opening of the IRA, and is caused by several fac-
tors.218 MVO is diagnosed immediately after PCI when post-
procedural angiographic TIMI flow is < 3, or in the case of a TIMI
flow of 3 when myocardial blush grade is 0 or 1, or when ST reso-
lution within 60–90 min of the procedure is < 70%. Other non-
invasive techniques to diagnose MVO are late gadolinium
enhancement (LGE) CMR (the current state of the art for MVO
identification and quantification), contrast echocardiography,
single-photon emission computed tomography (SPECT), and posi-
tron emission tomography (PET).218 Different strategies, such as
coronary post-conditioning, remote ischaemic conditioning, early
i.v. metoprolol, GP IIb/IIIa inhibitors, drugs targeting mitochondrial
integrity or nitric oxide pathways, adenosine, glucose modulators,
hypothermia, and others, have been shown to be beneficial in pre-
clinical and small-scale clinical trials,217,219 but still there is no ther-
apy aimed at reducing ischaemia/reperfusion injury (MI size) that is
clearly associated with improved clinical outcomes. The reduction
of ischaemia/reperfusion injury in general, and MVO in particular,
remains an unmet need to further improve long-term ventricular
function in STEMI.
5.3 Fibrinolysis and pharmacoinvasive
strategy
5.3.1 Benefit and indication of fibrinolysis
Fibrinolytic therapy is an important reperfusion strategy in settings
where primary PCI cannot be offered in a timely manner, and pre-
vents 30 early deaths per 1000 patients treated within 6 h after
symptom onset.220 The largest absolute benefit is seen among
patients at highest risk, including the elderly, and when treatment
is offered <2 h after symptom onset.138,221 Fibrinolytic therapy is
recommended within 12 h of symptom onset if primary PCI can-
not be performed within 120 min from STEMI diagnosis (see Figure
3) and there are no contraindications. The later the patient
presents (particularly after 3 h),98,120,121 the more consideration
should be given to transfer for primary PCI (as opposed to admin-
istering fibrinolytic therapy) because the efficacy and clinical bene-
fit of fibrinolysis decrease as the time from symptom onset
increases.120 In the presence of contraindications for fibrinolytic
treatment, it is important to weigh the potentially life-saving
effect of fibrinolysis against potentially life-threatening side effects,
taking into account alternative treatment options such as delayed
primary PCI.
Table 6 Doses of antiplatelet and anticoagulant
cotherapies in patients undergoing primary percutane-
ous coronary intervention or not reperfused
b.i.d. = twice a day; GP = glycoprotein; i.v. = intravenous; IU = international units;
PCI = percutaneous coronary intervention; UFH = unfractionated heparin.
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listed in Table 7.
5.3.2 Pre-hospital fibrinolysis
In a meta-analysis of six randomized trials (n = 6434), pre-hospital
fibrinolysis reduced early mortality by 17% compared with in-hospital
fibrinolysis,123 particularly when administered in the first 2 h of symp-
tom onset.138 These and more recent data support pre-hospital
initiation of fibrinolytic treatment when a reperfusion strategy is indi-
cated.97,99,100,237 The STREAM trial showed that pre-hospital fibrinol-
ysis followed by an early PCI strategy was associated with a similar
outcome as transfer for primary PCI in STEMI patients presenting
within 3 h after symptom onset who could not undergo primary PCI
within 1 h after FMC.121,238
If trained medical or paramedical staff are able to analyse the ECG on-
site or to transmit the ECG to the hospital for interpretation, it is
Fibrinolytic therapy
Recommendations Classa Levelb
When fibrinolysis is the reperfusion strategy, it is recommended to initiate this treatment as soon as possible after STEMI
diagnosis, preferably in the pre-hospital setting.96,98,123,222
I A
A fibrin-specific agent (i.e. tenecteplase, alteplase, or reteplase) is recommended.223,224 I B
A half-dose of tenecteplase should be considered in patients 75 years of age.121 IIa B
Antiplatelet co-therapy with fibrinolysis
Oral or i.v. aspirin is indicated.213 I B
Clopidogrel is indicated in addition to aspirin.225,226 I A
DAPT (in the form of aspirin plus a P2Y12 inhibitor
c) is indicated for up to 1 year in patients undergoing fibrinolysis and
subsequent PCI.
I C
Anticoagulation co-therapy with fibrinolysis
Anticoagulation is recommended in patients treated with lytics until revascularization (if performed) or for the duration of
hospital stay up to 8 days.199,224,227–233 The anticoagulant can be:
• Enoxaparin i.v. followed by s.c. (preferred over UFH).227–232
• UFH given as a weight-adjusted i.v. bolus followed by infusion.224
• In patients treated with streptokinase: fondaparinux i.v. bolus followed by an s.c. dose 24 h later.199,233
I A
I A
I B
IIa B
Transfer after fibrinolysis
Transfer to a PCI-capable centre following fibrinolysis is indicated in all patients immediately after fibrinolysis.121,124,126–130,234 I A
Interventions following fibrinolysis
Emergency angiography and PCI if indicated is recommended in patients with heart failure/shock.124, 235 I A
Rescue PCI is indicated immediately when fibrinolysis has failed (<50% ST-segment resolution at 60–90 min) or at any time in
the presence of haemodynamic or electrical instability, or worsening ischaemia.121,124,236
I A
Angiography and PCI of the IRA, if indicated, is recommended between 2 and 24 h after successful fibrinolysis.125–128,234 I A
Emergency angiography and PCI if needed is indicated in the case of recurrent ischaemia or evidence of reocclusion after initial
successful fibrinolysis.124 I B
DAPT = dual antiplatelet therapy; IRA = infarct-related artery; i.v. = intravenous; PCI = percutaneous coronary intervention; SBP = systolic blood pressure; s.c. = subcutaneous;
STEMI = ST-segment elevation myocardial infarction; UFH = unfractionated heparin.
aClass of recommendation.
bLevel of evidence.
cClopidogrel is the P2Y12 inhibitor of choice as co-adjuvant and after fibrinolysis, but 48 h after fibrinolysis, switch to prasugrel/ticagrelor may be considered in patients who
underwent PCI.
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..recommended to initiate fibrinolytic therapy in the pre-hospital
setting. The aim is to start fibrinolytic therapy within 10 min from STEMI
diagnosis.
5.3.3 Angiography and percutaneous coronary
intervention after fibrinolysis (pharmacoinvasive
strategy)
Following initiation of lytic therapy, it is recommended to transfer the
patients to a PCI centre (Figure 3). In cases of failed fibrinolysis, or if
there is evidence of reocclusion or reinfarction with recurrence of
ST-segment elevation, immediate angiography and rescue PCI is indi-
cated.124 In this setting, re-administration of fibrinolysis has not been
shown to be beneficial and should be discouraged.124 Even if it is
likely that fibrinolysis will be successful (ST-segment resolution
> 50% at 60–90 min; typical reperfusion arrhythmia; and disappear-
ance of chest pain), a strategy of routine early angiography is recom-
mended if there are no contraindications. Several randomized
trials126–128,234,239,240 and meta-analyses129,130 have shown that early
routine angiography with subsequent PCI (if needed) after
fibrinolysis reduced the rates of reinfarction and recurrent ischaemia
compared with a ‘watchful waiting’ strategy, in which angiography
and revascularization were indicated only in patients with spontane-
ous or induced severe ischaemia or LV dysfunction, or in those with a
positive outpatient ischaemia test. The benefits of early routine PCI
after fibrinolysis were seen in the absence of an increased risk of
adverse events (stroke or major bleeding), and across patient sub-
groups.241 Thus, early angiography with subsequent PCI if indicated is
also the recommended standard of care after successful fibrinolysis
(see Figure 3).
A crucial issue is the optimal time delay between successful lysis and
PCI; there was a wide variation in delay in trials, from a median of 1.3 h
in the Combined Angioplasty and Pharmacological Intervention versus
Thrombolytics ALone in Acute Myocardial Infarction (CAPITAL AMI)
trial240 to 17 h in the Grupo de Analisis de la Cardiopatıa Isquémica
Aguda (GRACIA)-1234 and STREAM trials.121 In a pooled patient-level
analysis of six randomized trials, very early angiography (<2 h) after
fibrinolysis was not associated with an increased risk of 30 day death/
reinfarction or in-hospital major bleeding, and a shorter time from
symptom onset to angiography (<4 h) was associated with reduced
30 day and 1 year death/reinfarction and 30 day recurrent ischaemia.125
Table 7 Doses of fibrinolytic agents and antithrombotic co-therapies
aPTT = activated partial thromboplastin time; eGFR = estimated glomerular filtration rate; i.v. = intravenous; IU = international units; rPA = recombinant plasminogen activator;
s.c. = subcutaneous; tPA = tissue plasminogen activator; UFH = unfractionated heparin.
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Based on this analysis, as well as on trials having a median delay
between start of lysis and angiography of 2–17 h,121,126–128 a time-
window of 2–24 h after successful lysis is recommended.
5.3.4 Comparison of fibrinolytic agents
A fibrin-specific agent should be preferred.224 Single-bolus weight-
adjusted tenecteplase tissue plasminogen activator (TNK-tPA) is
equivalent to accelerated tPA in reducing 30 day mortality, but is
safer in preventing non-cerebral bleeds and blood transfusion, and is
easier to use in the pre-hospital setting.223
5.3.5 Adjunctive antiplatelet and anticoagulant therapies
An early study showed that the benefits of aspirin and fibrinolytics
(i.e. streptokinase) were additive.213 The first dose of aspirin should
be chewed or given i.v. and a low dose (75–100 mg) given orally daily
thereafter. Clopidogrel added to aspirin reduces the risk of cardio-
vascular events and overall mortality in patients treated with fibrinol-
ysis225,226 and should be added to aspirin as an adjunct to lytic
therapy. Prasugrel and ticagrelor have not been studied as adjuncts to
fibrinolysis. There is no evidence that administration of GP IIb/IIIa
inhibitors improves myocardial perfusion or outcomes in patients
treated with fibrinolysis, and bleeding may increase.242
Parenteral anticoagulation should preferably be given until revascula-
rization (if performed). Otherwise, it should be given for at least 48 h
or for the duration of hospital stay, up to 8 days. In spite of an increased
risk of major bleeding, the net clinical benefit favoured enoxaparin over
UFH in the ASsessment of the Safety and Efficacy of a New
Thrombolytic 3 (ASSENT 3) trial (n = 6095).227 In the large
Enoxaparin and Thrombolysis Reperfusion for Acute myocardial
infarction Treatment–Thrombolysis In Myocardial Infarction
25 (ExTRACT–TIMI 25) trial (n = 20 506), a lower dose of enoxaparin
was given to patients75 years of age and to those with impaired renal
function (estimated creatinine clearance <30 mL/min). Enoxaparin was
associated with a reduction in the risk of death and reinfarction at 30
days when compared with a weight-adjusted UFH dose, but at the cost
of a significant increase in non-cerebral bleeding complications. The net
clinical benefit (i.e. absence of death, non-fatal infarction, and intracra-
nial haemorrhage) favoured enoxaparin.229,230 Finally, fondaparinux
was shown in the large OASIS-6 trial to be superior in this setting to
placebo or UFH in preventing death and reinfarction,199,233 especially
in patients who received streptokinase.
In a large trial with streptokinase,243 significantly fewer reinfarc-
tions were seen with bivalirudin given for 48 h compared with UFH,
though at the cost of a modest and non-significant increase in non-
cerebral bleeding complications. Bivalirudin has not been studied
with fibrin-specific agents. Thus, there is no evidence in support of
direct thrombin inhibitors as an adjunct to fibrinolysis.
Weight-adjusted i.v. tenecteplase, aspirin, and clopidogrel given
orally, and enoxaparin i.v. followed by s.c. administration until the
time of PCI (revascularisation), comprise the antithrombotic cocktail
most extensively studied as part of a pharmacoinvasive
strategy.121,126,128,242,244
5.3.6 Hazards of fibrinolysis
Fibrinolytic therapy is associated with a small but significant excess of
strokes, largely attributable to cerebral haemorrhage, with the excess
hazard appearing on the first day after treatment.220 Advanced age,
lower weight, female sex, previous cerebrovascular disease, and systolic
and diastolic hypertension on admission are significant predictors of
intracranial haemorrhage.245 In the latest trials, intracranial bleeding
occurred in 0.9–1.0% of the total population studied.121,223,246 In the
STREAM trial, the initial excess in intracranial haemorrhage in patients
75 years was reduced after the protocol amendment to reduce the
dose of tenecteplase by 50%. Data from a number of studies suggest
that major non-cerebral bleeds occurred in 4–13% of the patients
treated.121,223,224,246 Administration of streptokinase may be associated
with hypotension, but severe allergic reactions are rare. Re-
administration of streptokinase should be avoided because of antibodies
that can impair its activity, and because of the risk of allergic reactions.
5.3.7 Contraindications to fibrinolytic therapy
Short successful resuscitation does not contraindicate fibrinolytic
therapy. In patients in refractory cardiac arrest, lytic therapy is not
effective, increases the risk of bleeding, and is therefore not recom-
mended. Prolonged, or traumatic but successful, resuscitation
increases bleeding risk and is a relative contraindication to fibrinoly-
sis.247 Table 8 lists the absolute and relative contraindications to fibri-
nolytic therapy.
Table 8 Contra-indications to fibrinolytic therapy
DBP = diastolic blood pressure; SBP = systolic blood pressure.
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5.4 Coronary artery bypass graft surgery
Emergent coronary artery bypass graft surgery (CABG) should be
considered for patients with a patent IRA but with unsuitable anat-
omy for PCI, and either a large myocardial area at jeopardy or with
cardiogenic shock.248 In patients with MI-related mechanical compli-
cations who require coronary revascularization, CABG is recom-
mended at the time of repair. In STEMI patients with failed PCI or
coronary occlusion not amenable to PCI, emergent CABG is infre-
quently performed because the benefits of surgical revascularization
in this setting are uncertain. As the delay to reperfusion is long, the
probabilities of myocardial salvage affecting prognosis are low and
the surgical risks are elevated.
In the absence of randomized data, optimal timing for non-
emergent CABG in stabilized post-MI patients should be determined
individually. A review of California discharge data compared patients
who underwent early (<3 days, n = 4676) versus delayed (3 days,
n = 4800) post-MI CABG.249 Patients who underwent early CABG
had a higher mortality rate (unadjusted mortality 5.6% vs. 3.8%;
propensity-adjusted odds ratio 1.40, 95% CI 1.12–1.74; P < 0.001),
with the highest mortality observed in patients on whom surgery was
performed on the day of the MI (8.2%). However, no differentiation
was made between NSTEMI and STEMI, and higher-risk patients were
more likely to be treated rapidly. Patients with haemodynamic deteri-
oration or who are at high risk of recurrent ischaemic events (i.e.
patients with a large area of myocardium at jeopardy due to critical
coronary stenoses or recurrent ischaemia) should be operated on as
soon as possible without waiting for the full recovery of platelet func-
tion following discontinuation of DAPT. For all other patients, a wait-
ing period of 3–7 days may be the best compromise (at least 3 days
following interruption of ticagrelor,187,250 5 days for clopidogrel, and 7
days for prasugrel),7 while it is recommended that aspirin is contin-
ued.251 The first aspirin administration post-CABG is recommended
6–24 h after surgery in the absence of ongoing bleeding events.252,253
6. Management during
hospitalization and at discharge
6.1 Coronary care unit/intensive cardiac
care unit
Following reperfusion, it is recommended to admit STEMI patients to
a CCU/ICCU or equivalent unit where continuous monitoring and
specialized care can be provided. The staff should be thoroughly famil-
iar with the management of ACS, arrhythmias, heart failure, mechani-
cal circulatory support, invasive and non-invasive haemodynamic
monitoring (arterial and pulmonary artery pressures), respiratory
monitoring, mechanical ventilation, and targeted temperature man-
agement. The unit should also be able to manage patients with serious
renal and pulmonary disease. The desirable organization, structure,
and criteria of the CCU/ICCU have been described in an ESC-Acute
Cardiovascular Care Association (ACCA) position paper.254
6.2 Monitoring
ECG monitoring for arrhythmias and ST-segment deviations is
recommended for at least 24 h after symptom onset in all STEMI
patients. Longer monitoring should be considered in patients at
intermediate- to high-risk for cardiac arrhythmias (those
with more than one of the following criteria: haemodynamically
unstable, presenting major arrhythmias, LVEF <40%, failed reper-
fusion, additional critical coronary stenoses of major vessels, or
complications related to PCI). Further monitoring for arrhythmias
depends on estimated risk. When a patient leaves the CCU/ICCU
or equivalent, monitoring may be continued by telemetry. It is
recommended that personnel adequately equipped and trained
to manage life-threatening arrhythmias and cardiac arrest accom-
pany patients who are transferred between facilities during
the time-window in which they require continuous rhythm
monitoring.
6.3 Ambulation
Early ambulation (day 1) is recommended in the majority of patients
and is facilitated by using the radial access for PCI. Patients with
extensive myocardial damage, heart failure, hypotension, or arrhyth-
mias may initially rest in bed before assessment of myocardial func-
tion and achievement of clinical stabilization. Prolongation of bed rest
and limitation of physical activity may occasionally be needed for
patients with large infarcts or with severe complications depending
on symptoms and ability.
6.4 Length of stay
The optimal length of stay in the CCU/ICCU and hospital should
be determined on an individual basis, according to the patient’s
cardiac risk, comorbidities, functional status, and social support.
Generalization of successful reperfusion and knowledge of coro-
nary anatomy has led to progressive reductions in length of stay
after STEMI, with significant reductions in 30 day mortality, sug-
gesting that earlier discharge is not associated with late mortal-
ity.255,256 Several studies have shown that low-risk patients with
successful primary PCI and complete revascularization can safely
be discharged from hospital on day 2 or day 3 after PCI.256–262
Candidates for early discharge after STEMI can be identified using
simple criteria [e.g. the Second Primary Angioplasty in Myocardial
Infarction (PAMI-II) criteria, the Zwolle primary PCI Index, or
other criteria].257,258 The PAMI-II criteria designate as low risk
patients aged <70 years, with an LVEF >45%, one- or two-vessel
disease, successful PCI, and no persistent arrhythmias. A short
hospital stay implies limited time for proper patient education and
up-titration of secondary prevention treatments. Consequently,
these patients should have early post-discharge consultations with
a cardiologist, primary care physician, or specialized nurse sched-
uled and be rapidly enrolled in a formal rehabilitation programme,
either in-hospital or on an outpatient basis.
Early (i.e. same day) transfer to a local hospital following successful
primary PCI is routine practice. This can be done safely under
adequate monitoring and supervision in selected patients, i.e. those
without signs or symptoms consistent with ongoing myocardial
ischaemia, without arrhythmia, who are haemodynamically stable,
not requiring vasoactive or mechanical support, and are not sched-
uled for further revascularization.263
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6.5 Special patient subsets
Several specific patient subsets deserve particular consideration.
6.5.1 Patients taking oral anticoagulation
Many patients presenting with STEMI are previously on oral anticoa-
gulation or require long-term anticoagulation afterwards. The addi-
tion of DAPT to oral anticoagulation increases the risk of bleeding
complications two- to three-fold compared to anticoagulation
alone.266–269
Management during STEMI: Given that oral anticoagulation is a rel-
ative contraindication for fibrinolysis, when these patients present
with a STEMI, they should be triaged for primary PCI strategy regard-
less of the anticipated time to PCI-mediated reperfusion. Patients
should receive additional parenteral anticoagulation, regardless of the
timing of the last dose of oral anticoagulant. GP IIb/IIIa inhibitors
should be avoided. Loading of aspirin should be done as in all STEMI
patients, and clopidogrel is the P2Y12 inhibitor of choice (600 mg
loading dose) before or at the latest at the time of PCI. Prasugrel and
ticagrelor are not recommended. Ideally, a chronic anticoagulation
regimen should not be stopped during admission. Gastric protection
with a proton pump inhibitor (PPI) is recommended.
Maintenance after STEMI: In general, continuation of oral anticoa-
gulation in patients with an indication for DAPT (e.g. after STEMI)
should be evaluated carefully and continued only if compelling evi-
dence exists. Ischaemic and bleeding risks should be taken into con-
sideration. While there is a considerable overlap of risk factors
associated with ischaemic with bleeding outcomes, multiple bleeding
risk scores outperform CHA2DS2-VASc [Cardiac failure,
Hypertension, Age 75 (Doubled), Diabetes, Stroke (Doubled) –
VAScular disease, Age 65–74 and Sex category (Female)] in predict-
ing bleeding risk.270,271
For most patients, triple therapy (in the form of oral anticoagula-
tion, aspirin, and clopidogrel) should be considered for 6 months.
Then, oral anticoagulation plus aspirin or clopidogrel should be con-
sidered for an additional 6 months. After 1 year, it is indicated to
maintain only oral anticoagulation. In cases of very high bleeding risk,
triple therapy can be reduced to 1 month after STEMI, continuing on
dual therapy (oral anticoagulation plus aspirin or clopidogrel) up to
1 year, and thereafter only anticoagulation.5,7
The dose intensity of oral anticoagulation should be carefully
monitored with a target international normalized ratio in the lower
part of the recommended target range. When non-vitamin K antago-
nist oral anticoagulants are used, the lowest effective tested dose for
stroke prevention should be applied. In general, dose reduction
below the approved dose is not recommended. Recently, the Open-
Label, Randomized, Controlled, Multicenter Study Exploring Two
Treatment Strategies of Rivaroxaban and a Dose-Adjusted Oral
Vitamin K Antagonist Treatment Strategy in Subjects with Atrial
Fibrillation who Undergo Percutaneous Coronary Intervention
(PIONEER AF-PCI) study randomized 2124 patients with non-
valvular AF, who had undergone PCI with stenting (12% STEMI
patients), to receive low-dose rivaroxaban [15 mg o.d. (once a day)]
plus a P2Y12 inhibitor (93% clopidogrel) and no aspirin for 12 months,
very-low-dose rivaroxaban (2.5 mg b.i.d.) plus DAPT (95% clopidog-
rel) for 1, 6, or 12 months, or standard therapy with a dose-adjusted
vitamin K antagonist plus DAPT (96% clopidogrel) for 1, 6, or
12 months.272 The primary safety endpoint (TIMI clinically significant
bleeding) was lower in the two groups receiving rivaroxaban. No dif-
ference in major bleeding or transfusion was observed across groups.
However, this study was underpowered for assessing differences in
ischaemic events such as stent thrombosis or stroke rates.
Therefore, uncertainty remains regarding the comparative perform-
ance of three tested antithrombotic regimens in patients at high
stroke and/or stent thrombosis risk.
6.5.2 Elderly patients
Owing to the ageing of the population, a higher proportion of elderly
patients is expected to present with STEMI. As these patients may
present with atypical symptoms, the diagnosis of MI may be delayed
or missed.27 In addition, the elderly have more comorbidities and are
less likely to receive reperfusion therapy compared with younger
Logistical issues for hospital stay
Recommendations Classa Levelb
It is indicated that all hospitals participating in the
care of STEMI patients have a CCU/ICCU equipped
to provide all aspects of care for STEMI patients,
including treatment of ischaemia, severe heart failure,
arrhythmias, and common comorbidities.
I C
Transfer back to a referring non-PCI hospital
Same day transfer should be considered appropri-
ate in selected patients after successful primary
PCI, i.e. those without ongoing myocardial ischae-
mia, arrhythmia, or haemodynamic instability, not
requiring vasoactive or mechanical support, and
not needing further early revascularization.263
IIa C
Monitoring
It is indicated that all STEMI patients have ECG
monitoring for a minimum of 24 h.
I C
Length of stay in the CCU
It is indicated that patients with successful reperfu-
sion therapy and an uncomplicated clinical course
are kept in the CCU/ICCU for a minimum of 24 h
whenever possible, after which they may be
moved to a step-down monitored bed for an addi-
tional 24–48 h.
I C
Hospital discharge
Early discharge (within 48–72 h) should be consid-
ered appropriate in selected low-risk patientsc if
early rehabilitation and adequate follow-up are
arranged.257,259–262,264,265
IIa A
CCU = coronary care unit; ICCU = intensive cardiac care unit; LVEF = left ven-
tricular ejection fraction; PAMI-II, Second Primary Angioplasty in Myocardial
Infarction; PCI = percutaneous coronary intervention; STEMI = ST-segment ele-
vation myocardial infarction.
aClass of recommendation.
bLevel of evidence.
cFor example, PAMI-II criteria: age <70 years, LVEF >45%, one- or two-vessel dis-
ease, successful PCI and no persistent arrhythmias.
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..patients.273,274 Elderly patients are also at particular risk of bleeding
and other complications from acute therapies because bleeding risk
increases with age, renal function tends to decrease, and the preva-
lence of comorbidities is high. Observational studies have shown fre-
quent excess dosing of antithrombotic therapies in elderly
patients.275 Furthermore, they have a higher risk of mechanical
complications.
It is key to maintain a high index of suspicion for MI in elderly
patients who present with atypical complaints, treating them as rec-
ommended, and using specific strategies to reduce bleeding risk;
these include paying attention to proper dosing of antithrombotic
therapies, particularly in relation to renal function, frailty, or comor-
bidities, and using radial access whenever possible. There is no upper
age limit with respect to reperfusion, especially with primary PCI.276
6.5.3 Renal dysfunction
Renal dysfunction [estimated glomerular filtration rate (eGFR)
<30 mL/min/1.73 m2] is present in approximately 30–40% of patients
with ACS and is associated with a worse prognosis and increased risk
of in-hospital complications.277 Owing to differences in presentation
(less frequent presentation with chest pain and fewer typical ECG
signs) diagnosis may be delayed.
Although decisions on reperfusion in patients with STEMI have to
be made before any assessment of renal function is available, it is
important to estimate the GFR as soon as possible. The type and
dose of antithrombotic agent (see Table 9) and the amount of con-
trast agent should be considered based on renal function.277 ACS
patients with chronic kidney disease (CKD) receive frequently excess
dosing with antithrombotics, contributing to the increased bleeding
risk.275 Consequently, in patients with known or anticipated reduc-
tion of renal function, several antithrombotic agents should either be
withheld or their doses reduced appropriately. Ensuring proper
hydration during and after primary PCI and limiting the dose of con-
trast agents, preferentially low-osmolality contrast agents, are impor-
tant steps in minimizing the risk of contrast-induced nephropathy.1
6.5.4 Non-reperfused patients
Patients who, for specific reasons (e.g. long delay), fail to receive reper-
fusion therapy within the recommended time (first 12 h) should imme-
diately be evaluated clinically to rule out the presence of clinical,
Table 9 Recommended doses of antithrombotic agents in the acute care of patients with chronic kidney disease
(eGFR 15 to <30 mL/min/1.73 m2)
70-100 IU/kg i.v. (50-70 IU/kg if concomitant with
GP IIb/IIIa inhibitors)
aPTT = activated partial thromboplastin time; CKD = chronic kidney disease; eGFR = estimated glomerular filtration rate; GP = glycoprotein; IU = international units; i.v. =
intravenous; PCI = percutaneous coronary intervention; s.c. = subcutaneous; UFH = unfractionated heparin.
aDouble bolus if administered during primary PCI.
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..haemodynamic, or electrical instability. A primary PCI strategy is indi-
cated in the presence of signs or symptoms suggestive of ongoing myo-
cardial ischaemia, heart failure, haemodynamic instability, or life-
threatening arrhythmias,141 and should be considered in stable asympto-
matic patients between 12–48 h after symptom onset.133,142 After that
time, either a non-invasive test for the presence of residual myocardial
ischaemia/viability to decide a late invasive strategy or elective coronary
angiography should be considered. However, routine PCI is not indi-
cated in totally occluded IRA beyond the first 48 h from symptom onset
due to the increased risk of late complications (see Figure 4).135,137
Early echocardiography with LVEF assessment is indicated in all
patients. Medical therapy should include DAPT, anticoagulation, and
Figure 4 Reperfusion strategies in the infarct-related artery according to time from symptoms onset. PCI = percutaneous coronary intervention;
STEMI = ST-segment elevation myocardial infarction.
In early presenters (i.e. those with STEMI diagnosis within 3 hours from symptoms onset), a primary PCI strategy is the reperfusion
strategy of choice. If the anticipated time from STEMI diagnosis to PCI-mediated reperfusion is > 120 min, then immediate fibrinolysis is
indicated. After 3 hours (and up to 12 hours) of symptoms onset, the later the patient presents, the more consideration should be given
to a primary PCI strategy as opposed to administering fibrinolytic therapy. In evolved STEMI (12–48 hours after symptoms onset), a
routine primary PCI strategy (urgent angiography and subsequent PCI if indicated) should be considered in all patients. After 48 hours
(recent STEMI) angiography should be performed but routine PCI of a total occluded IRA is not recommended. Regardless of the time
from symptoms onset, the presence of ongoing symptoms suggestive of ischaemia, haemodynamic instability, or lifethreatening arrhyth-
mias is an indication for a primary PCI strategy.
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..secondary prevention therapies. In patients in whom PCI is finally
performed, ticagrelor or prasugrel are preferred,186,187 while in
patients who do not undergo PCI, clopidogrel is indicated.225
Anticoagulation, preferably with fondaparinux, is indicated until coro-
nary revascularisation is done or hospital discharge.199 These patients
are often undertreated. Therefore, it is important to emphasize that
they should receive all the same secondary prevention medical thera-
pies as those who receive timely reperfusion.
6.5.5 Patients with diabetes
Patients with diabetes are known to present with atypical chest
pain more frequently than patients without diabetes and conse-
quently may receive delayed initiation of treatment.278 In addition,
diabetic patients are characterized by a more diffuse atheroscler-
otic disease.279 Although patients with diabetes are at higher risk of
death and complications (including repeat revascularization after
PCI), selection of antithrombotic therapies and reperfusion ther-
apy is the same as in patients without diabetes. Regarding the use
of antiplatelet drugs, the more potent oral P2Y12 receptor inhibi-
tors (prasugrel or ticagrelor) have consistently shown increased
relative benefits with higher absolute risk reductions in patients
with diabetes compared with clopidogrel.280 On admission, it is
recommended to evaluate glycaemic status in all STEMI patients
with and without a known history of diabetes or hyperglycaemia,
and to monitor it frequently in diabetic patients and patients with
hyperglycaemia. In critically ill patients, there is a high risk of
hypoglycaemia-related events when using intensive insulin ther-
apy.281 In the absence of robust data to guide the optimal glucose
management (e.g. treatment thresholds and glucose targets) in
STEMI patients, a close but not too strict glucose control seems
the best approach. In the acute phase, it is reasonable to manage
hyperglycaemia (i.e. maintain a blood glucose concentration
<_11.0 mmol/L or 200 mg/dL) but absolutely avoid hypoglycae-
mia.282 To assess the risk of renal insufficiency, it is recommended
to measure eGFR in patients on metformin and/or sodium-glucose
co-transporter-2 (SGLT2) inhibitors.
6.6. Risk assessment
6.6.1 Clinical risk assessment
All patients with STEMI should have an early assessment of short-
term risk, including an evaluation of the extent of myocardial damage,
the occurrence of successful reperfusion, and the presence of clinical
markers of high risk of further events including older age, fast heart
rate, hypotension, Killip class >I, anterior MI, previous MI, elevated
initial serum creatinine, history of heart failure, or peripheral arterial
disease. Several risk scores have been developed, based on readily
identifiable parameters in the acute phase before reperfusion.264,283
The Global Registry of Acute Coronary Events (GRACE) risk score
is recommended for risk assessment and adjustment.283,284 All
patients should also have an evaluation of long-term risk before
discharge, including LVEF, severity of CAD and completeness of cor-
onary revascularization, residual ischaemia, occurrence of complica-
tions during hospitalization, and levels of metabolic risk markers,
including total cholesterol, low-density lipoprotein cholesterol (LDL-
C), high-density lipoprotein cholesterol (HDL-C), fasting triglycer-
ides, and plasma glucose, as well as renal function. As LDL-C levels
tend to decrease during the first days after MI, they should be meas-
ured as soon as possible after admission.
Patients who do not get successful reperfusion are at higher risk of
early complications and death. These patients should have an assess-
ment of the presence of residual ischaemia and, if appropriate, myo-
cardial viability. Because the risk of events decreases with time, early
risk assessment is indicated.
6.6.2 Non-invasive imaging in management and risk
stratification
LV dysfunction is a key prognostic factor. Therefore, it is recom-
mended that the LVEF is determined before hospital discharge in all
STEMI patients. Emergency echocardiography at presentation is indi-
cated in patients with cardiac arrest, cardiogenic shock, haemody-
namic instability or suspected mechanical complications, and if the
diagnosis of STEMI is uncertain. Routine echocardiography after pri-
mary PCI is recommended to assess resting LV function, as well as
Management of hyperglycaemia
Recommendations Classa Levelb
It is recommended to measure glycaemic status at initial evaluation in all patients, and perform frequent monitoring in patients
with known diabetes or hyperglycaemia (defined as glucose levels11.1 mmol/L or 200mg/dL)
I C
In patients on metformin and/or SGLT2 inhibitors, renal function should be carefully monitored for at least 3 days after
coronary angiography/PCI.c
I C
Glucose-lowering therapy should be considered in ACS patients with glucose levels >10 mmol/L (>180 mg/dL), while
episodes of hypoglycaemia (defined as glucose levels <_3.9 mmol/L or <_ 70 mg/dL) should be avoided.
IIa C
Less stringent glucose control should be considered in the acute phase in patients with more advanced cardiovascular
disease, older age, longer diabetes duration, and more comorbidities.
IIa C
ACS = acute coronary syndrome; PCI = percutaneous coronary intervention; SGLT2 = sodium-glucose co-transporter-2.
aClass of recommendation.
bLevel of evidence.
cA short withdrawal of metformin may be considered after an invasive coronary procedure.
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RV and valve function, to exclude early post-infarction mechanical
complications and LV thrombus. This assessment is usually per-
formed with echocardiography, but in the limited cases in which
echocardiography may be suboptimal or inconclusive, CMR may be a
good alternative. Patients with multivessel disease in which only the
IRA lesion has been treated, or patients with late-presenting STEMI,
may benefit from additional assessment for residual ischaemia or via-
bility. Treatment of non-IRA lesions in patients with multivessel dis-
ease is discussed in section 5.2.1.4. In patients presenting days after
the acute event with a completed MI, the presence of recurrent
angina or documented ischaemia and proven viability in a large myo-
cardial territory may help define a strategy of planned revasculariza-
tion of an occluded IRA,135,285,286 although the evidence is
controversial.
The timing of and best imaging technique (echocardiography,
SPECT, CMR, or PET) to detect residual ischaemia and myocardial
viability remains to be determined, but will also depend on local avail-
ability and expertise. The best validated and widely available tests are
stress echocardiography and SPECT (both used in combination with
exercise or pharmacological stress), but PET and CMR are equally
indicated. However, in post-MI patients, the detection of residual
ischaemia by echocardiography is challenging due to existing wall
motion abnormalities.287 LGE-CMR imaging has a high diagnostic
accuracy for assessing the transmural extent of myocardial scar tis-
sue.288 However, the ability to detect viability and predict recovery
of wall motion is not significantly superior to other imaging techni-
ques.289 The presence of dysfunctional viable myocardium by LGE-
CMR is an independent predictor of mortality in patients with ischae-
mic LV dysfunction.290
More recently, the presence of wall thinning with limited scar bur-
den was shown to be associated with improved contractility and res-
olution of wall thinning after revascularization, emphasizing the
importance of viability beyond wall thickness and myocardial revascu-
larization to improve prognosis.291 PET is also a high-resolution tech-
nique but its use is limited by cost and availability. A randomized
clinical trial with PET imaging demonstrated that patients with a sub-
stantial amount of dysfunctional but viable myocardium are likely to
benefit from myocardial revascularization and may show improve-
ments in regional and global contractile function, symptoms, exercise
capacity, and long-term prognosis.292 The association between viabil-
ity and improved survival after revascularisation was also demon-
strated by a meta-analysis.293
In patients with a pre-discharge LVEF <_40%, re-evaluation of
LVEF 6–12 weeks after complete revascularization and optimal
medical therapy is recommended to assess the potential need for
primary prevention implantable cardioverter defibrillator (ICD)
implantation.3 Additional parameters that are measured by imag-
ing in these patients and that could be used as endpoints in clinical
trials are: (1) infarct size (CMR, SPECT, and PET); (2) myocar-
dium at risk (SPECT, CMR); (3) MVO (CMR); and (4) intra-
myocardial haemorrhage (CMR). Infarct size and MVO are pre-
dictors of long-term mortality and heart failure in STEMI
survivors.216,217,294
Summary of indications for imaging and stress testing
in ST-elevation myocardial infarction patients
Recommendations Classa Levelb
At presentation
Emergency echocardiography is indicated in
patients with cardiogenic shock and/or haemody-
namic instability or suspected mechanical compli-
cations without delaying angiography.295
I C
Emergency echocardiography before coronary
angiography should be considered if the diagnosis
is uncertain.295
IIa C
Routine echocardiography that delays emergency
angiography is not recommended.295
III C
Coronary CT angiography is not recommended III C
During hospital stay (after primary PCI)
Routine echocardiography to assess resting LV
and RV function, detect early post-MI mechanical
complications, and exclude LV thrombus is rec-
ommended in all patients.296,297
I B
Emergency echocardiography is indicated in hae-
modynamically unstable patients.295
I C
When echocardiography is suboptimal/inconclu-
sive, an alternative imaging method (CMR prefera-
bly) should be considered.
IIa C
Either stress echo, CMR, SPECT, or PET may be
used to assess myocardial ischaemia and viability,
including in multivessel CAD.1,298–300
IIb C
After discharge
In patients with pre-discharge LVEF <_40%, repeat
echocardiography 6–12 weeks after MI, and after
complete revascularization and optimal medical
therapy, is recommended to assess the potential
need for primary prevention ICD
implantation.3,296
I C
When echo is suboptimal or inconclusive, alterna-
tive imaging methods (CMR preferably) should be
considered to assess LV function.
IIa C
CAD = coronary artery disease; CMR = cardiac magnetic resonance; CT = com-
puted tomography; ICD = implantable cardioverter defibrillator; LV = left ven-
tricular; LVEF = left ventricular ejection fraction; MI = myocardial infarction; PCI
= percutaneous coronary intervention; PET = positron emission tomography; RV
= right ventricular; SPECT = single-photon emission computed tomography.
aClass of recommendation.
bLevel of evidence.
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7. Long-term therapies for
ST-segment elevation myocardial
infarction
7.1 Lifestyle interventions and risk factor
control
Key lifestyle interventions include cessation of smoking, optimal
blood pressure control, diet advice and weight control, and encour-
aging physical activity. Detailed recommendations are available from
the ESC Guidelines on prevention.4 During hospitalization, the time
for implementing secondary prevention is limited and a close collabo-
ration between the cardiologist and the general practitioner, special-
ist rehabilitation nurses, pharmacists, dieticians, and physiotherapists
is critically important. Habits of a lifetime are not easily changed, and
the implementation and follow-up of these changes are a long-term
undertaking.
7.1.1 Smoking cessation
Smoking has a strong pro-thrombotic effect, and smoking cessation is
potentially the most (cost) effective of all secondary prevention
measures.301 Smoking cessation interventions should start during
hospitalization, when smoking is not allowed, and continue during the
post-discharge follow-up period.302,303 The beneficial effect of smok-
ing cessation in patients with CAD, including a majority suffering an
MI, has been shown in a meta-analysis (20 observational studies,
including 12 603 patients) reporting a 36% reduction of mortality in
quitters.304
A significant number of CAD patients continue or restart smoking,
illustrating the addictive nature of the smoking habit.305 There is a
strong evidence base for brief interventions, with a combination of
behavioural support and pharmacotherapies including nicotine
replacement therapy, bupropion, and varenicline.305,306 Electronic
cigarettes may also be helpful in achieving smoking cessation, as there
is some evidence from two pooled randomized clinical trials (662
patients) showing that electronic cigarettes with nicotine had higher
quit or reduced smoking rates when compared with placebo.307
7.1.2 Diet, alcohol, and weight control
Current guidelines on prevention recommend: (i) a diet similar to the
Mediterranean diet, which includes a maximum of 10% of total
energy intake from saturated fat, by replacing it with polyunsaturated
fatty acids and as little as possible of trans fatty acids; (ii) salt intake
of < 5 g per day; (iii) 30–45 g fibre per day; (iv)200 g fruits and 200 g
vegetables per day; (v) fish 1–2 times per week (especially oily vari-
eties); (vi) 30 g unsalted nuts daily; (vii) limited alcohol intake [maxi-
mum of 2 glasses (20 g of alcohol) daily for men and 1 for women];
and (viii) discouraging sugar-sweetened drinks.4 Moderate alcohol
consumption in abstainers is not recommended.
Overweight and obesity [body mass index (BMI) 25 kg/m2] is
associated with higher all-cause mortality compared with a healthy
weight (BMI between 20 kg/m2 and <25 kg/m2). Abdominal fat is par-
ticularly harmful and weight loss has beneficial effects on cardiovascu-
lar disease risk factors. Consequently, maintaining a healthy weight or
losing weight is recommended for all subjects,308 including patients
with STEMI. However, it has not been established that weight reduc-
tion per se reduces mortality.
7.1.3 Exercise-based cardiac rehabilitation
All AMI patients should participate in an exercise-based cardiac reha-
bilitation programme,309 taking into account their age, pre-infarction
level of activity, and physical limitations. A cardiac rehabilitation pro-
gramme preferably includes exercise training, risk factor modification,
education, stress management, and psychological support.309 In a large
meta-analysis, exercise training as part of a cardiac rehabilitation pro-
gramme was associated with a 22% reduction in cardiac mortality rate
in patients with CAD.309 The benefit of cardiac rehabilitation appears
to be through direct physiological effects of exercise training and
through cardiac rehabilitation effects on risk factor control, lifestyle
behaviours, and mood.310 An additional benefit in the context of a
short hospital stay is to ensure proper titration and monitoring of key,
evidence-based therapies after STEMI. Nowadays, most rehabilitation
is offered as an outpatient programme of 8–24 weeks’ duration.311,312
7.1.4 Resumption of activities
Return to work after AMI represents an important indicator of
recovery. Younger women in particular are at greater risk of not
returning to work, given evidence of their worse recovery after MI
than similarly aged men.313 Decisions should be individualized, based
on LV function, completeness of revascularization and rhythm con-
trol, and the job characteristics. Extended sick leave is usually not
beneficial and light-to-moderate physical activity after discharge
should be encouraged. Sexual activity can be resumed early if
adjusted to physical ability.
Guidance on air travel including repatriation for patients suffering
an MI abroad is constrained by limited data. Factors related to the
clinical circumstances as well as length of travel, whether accompa-
nied, and the degree of anxiety also play a role. For uncomplicated
completely revascularized MI with LVEF >40% the risk is low and
travelling is regarded as safe after hospital discharge (from day 3
onwards). In complicated STEMI, including patients with heart failure,
LVEF <40%, residual ischaemia, and arrhythmia, travelling should be
deferred until the condition is stable.314
7.1.5 Blood pressure control
Hypertension is a prevalent risk factor in patients admitted with
STEMI and, consequently, blood pressure should be well controlled.
In addition to lifestyle changes, including reduced salt intake,
increased physical activity, and weight loss, pharmacotherapy with a
systolic blood pressure (SBP) target of < 140 mmHg should be initi-
ated. In elderly, frail patients, the target can be more lenient, whereas
in patients at very high risk who tolerate multiple blood pressure-
lowering drugs, a target of < 120 mmHg may be considered.4,315,316
Despite the proven efficacy of this treatment, non-adherence to life-
style interventions and medications may affect treatment effect.
7.1.6 Adherence to treatment
Low treatment adherence is an important barrier to achieving opti-
mal treatment targets and is associated with worse outcomes.317
Delayed outpatient follow-up after AMI results in worse short- and
long-term medication adherence.318 In a meta-analysis of 376 162
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patients, adherence to cardiovascular medications was estimated to
be about 57% after a median of 2 years.319
It is generally recognized that adherence is determined by the
interplay of socioeconomic, medication-related, condition-related,
health system-related, and patient-related factors.320 A strategy to
reduce poor adherence is the use of a fixed-dose combination or pol-
ypill, including key medications to reduce cardiovascular risk, as a
once-daily dose pill.321,322 The only study dedicated to post-MI
patients is the recent phase 2 Fixed-Dose Combination Drug for
Secondary Cardiovascular Prevention (FOCUS) trial,323 in which 695
patients post-MI were randomized to usual care or to a polypill-
based strategy [polypill containing aspirin, an angiotensin-converting
enzyme (ACE) inhibitor, and a statin]. In this trial, after 9 months of
follow-up, the polypill group showed improved adherence compared
with the group receiving separate medications. Larger trials are
needed to confirm a clinical benefit in secondary prevention.
Although low adherence has been qualified as an ubiquitous prob-
lem,324 healthcare professionals and patients should be aware of this
challenge and optimize communication by providing clear informa-
tion, simplify treatment regimens, aim at shared decision-making, and
implement repetitive monitoring and feedback.
7.2 Antithrombotic therapy
Full text about long-term antithrombotic therapy can be found in the
online Web Addenda. In addition, this topic is covered in great detail
in the ESC Focused Update on DAPT in CAD published simultane-
ously with these guidelines.7
7.2.1 Aspirin
Aspirin is recommended indefinitely in all patients with STEMI.329,330
For long-term prevention, low aspirin doses (75–100 mg) are indi-
cated due to similar anti-ischaemic and less adverse events than
higher doses, as demonstrated in the CURRENT-OASIS 7 trial.330
7.2.2 Duration of dual antiplatelet therapy and
antithrombotic combination therapies
DAPT, combining aspirin and a P2Y12 inhibitor (i.e. prasugrel, ticagre-
lor, or clopidogrel), is recommended in patients with STEMI who are
undergoing primary PCI (for up to 12 months).186,187 Clopidogrel is
recommended for 1 month in patients treated with fibrinolysis with-
out subsequent PCI.225,226 Expanding the duration of DAPT up to
12 months should be considered in these patients.
For patients undergoing fibrinolysis and subsequent PCI, DAPT is
recommended for 12 months. Clopidogrel is the P2Y12 inhibitor of
choice as co-adjuvant and after fibrinolysis. Potent P2Y12 inhibitors
have not been properly tested in patients undergoing fibrinolysis, and
safety (i.e. bleeding complications) is not well established. However,
in patients who underwent PCI after fibrinolysis, after a safety period
(arbitrarily considered 48 h), there are no biological grounds to con-
sider that potent P2Y12 inhibitors will add risk and not exert a benefit
over clopidogrel as in the primary PCI setting.
Whereas no dedicated study exists on optimal DAPT duration in
patients at high bleeding risk, multiple studies have shown that short-
ening DAPT to 6 months, compared with 12 months or longer,
reduces the risk of major bleeding complications, with no apparent
trade-off in ischaemic events.331,332
Two major studies have shown the benefit towards reduction of
non-fatal ischaemic events in patients receiving longer than
12 months of DAPT.333,334 The DAPT Study included only roughly
10% of STEMI patients and no information has so far been provided
with respect to the benefit of prolonging clopidogrel or prasugrel
from 12 to 30 months in this patient subset. Hence, no formal recom-
mendations are possible for the use of clopidogrel or prasugrel
beyond 1 year.334
More recently, the Prevention of Cardiovascular Events in Patients
with Prior Heart Attack Using Ticagrelor Compared to Placebo on a
Background of Aspirin–Thrombolysis in Myocardial Infarction 54
(PEGASUS-TIMI 54) trial examined two doses of ticagrelor (60 mg
and 90 mg b.i.d.) vs. placebo in patients with a history of MI 1–3 years
previously and with high-risk features; the study showed a reduction
in MACE with 90 mg ticagrelor.333 There was no reduction in total
mortality, but there was a borderline signal towards reduced cardio-
vascular mortality (when both doses were pooled) consistent with
the reduction in non-fatal outcomes.333 The 60 mg (but not the
90 mg) ticagrelor (plus aspirin) regimen also significantly reduced the
stroke risk compared with aspirin monotherapy. The ticagrelor regi-
men was associated with a significantly increased bleeding risk.
Patients with previous STEMI comprised more than 50% of the over-
all PEGASUS-TIMI 54 population, and subgroup analysis has shown
consistent results in patients with previous STEMI vs. NSTEMI.333
According to the available data, extension of DAPT beyond 1 year
(up to 3 years) in the form of aspirin plus ticagrelor 60 mg b.i.d. may
be considered in patients who have tolerated DAPT without a bleed-
ing complication and having one additional risk factor for ischaemic
events.
Gastric protection with a PPI is recommended for patients with a
history of gastrointestinal bleeding and is appropriate for patients
with multiple risk factors for bleeding, such as advanced age, concur-
rent use of anticoagulants, steroids or non-steroidal anti-inflamma-
tory drugs including high-dose aspirin, and Helicobacter pylori
infection.335–337
Behavioural aspects after ST-elevation myocardial
infarction
Recommendations Classa Levelb
It is recommended to identify smokers and
provide repeated advice on stopping, with offers
to help with the use of follow-up support, nicotine
replacement therapies, varenicline, and bupropion
individually or in combination.4,302,303,325–327
I A
Participation in a cardiac rehabilitation programme
is recommended.4,309,328
I A
A smoking cessation protocol is indicated for each
hospital participating in the care of STEMI patients.
I C
The use of the polypill and combination therapy
to increase adherence to drug therapy may be
considered.4,322,323
IIb B
STEMI = ST-segment elevation myocardial infarction.
aClass of recommendation.
bLevel of evidence.
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In the Acute Coronary Syndrome–Thrombolysis In Myocardial
Infarction 51 (ATLAS ACS 2–TIMI 51) trial (n = 15 526, 50% STEMI),
a low dose of rivaroxaban (2.5 mg twice daily), on top of aspirin plus
clopidogrel, reduced the composite primary endpoint of cardiovas-
cular death, MI, or stroke, but also all-cause mortality, over a mean
follow-up of 13 months.338 Stent thrombosis was reduced by one-
third. However, this was associated with a three-fold increase in non-
CABG-related major bleeding and intracranial haemorrhage.338
Based on the ATLAS ACS 2–TIMI 51 trial, in selected patients at low
bleeding risk, the 2.5 mg dose of rivaroxaban may be considered in
patients who receive aspirin and clopidogrel after STEMI.
7.3 Beta-blockers
7.3.1 Early intravenous beta-blocker administration
In patients undergoing fibrinolysis, early i.v. beta-blocker treatment
reduces the incidence of acute malignant ventricular arrhythmias,
although there is no clear evidence of long-term clinical
benefit.344–346
In patients undergoing primary PCI, the Effect of Metoprolol in
Cardioprotection During an Acute Myocardial Infarction
(METOCARD-CNIC) trial (n = 270) showed that the very early
administration of i.v. metoprolol (15 mg) at the time of diagnosis
in patients with anterior STEMI, no signs of heart failure, and
SBP >120 mmHg was associated with a reduction in infarct
size measured by CMR at 5–7 days (25.6 g vs. 32.0 g; P = 0.012),
and higher LVEF at 6 months CMR (48.7% vs. 45.0%; P = 0.018)
compared with control treatment.347,348 All patients without con-
traindications received oral metoprolol within 24 h. The
incidence of MACE (composite of death, admission as a result of
heart failure, reinfarction, or malignant ventricular arrhythmias) at
2 years was 10.8% vs. 18.3% in the i.v. metoprolol and control
arms (P = 0.065).348 Metoprolol treatment was associated with a
significant reduction in the incidence and extent of MVO.349 The
Early Intravenous Beta-Blockers in Patients With ST-Segment
Elevation Myocardial Infarction Before Primary Percutaneous
Coronary Intervention (EARLY-BAMI) trial randomized
683 patients with STEMI within 12 h of onset to i.v. metoprolol
(5 mg at recruitment and an additional 5 mg immediately before
PCI) or placebo.350 All patients without contraindications
Maintenance antithrombotic strategy after ST-elevation myocardial infarction
Recommendations Classa Levelb
Antiplatelet therapy with low-dose aspirin (75–100 mg) is indicated.329 I A
DAPT in the form of aspirin plus ticagrelor or prasugrel (or clopidogrel if ticagrelor or prasugrel are not available or are contraindicated), is
recommended for 12 months after PCI, unless there are contraindications such as excessive risk of bleeding.186,187
I A
A PPI in combination with DAPT is recommended in patients at high risk of gastrointestinal bleedingc.335–337 I B
In patients with an indication for oral anticoagulation, oral anticoagulants are indicated in addition to antiplatelet therapy.5 I C
In patients who are at high risk of severe bleeding complications, discontinuation of P2Y12 inhibitor therapy after 6 months should be
considered.332,339,340
IIa B
In STEMI patients with stent implantation and an indication for oral anticoagulation, triple therapyd should be considered for 1–6 months
(according to a balance between the estimated risk of recurrent coronary events and bleeding).5
IIa C
DAPT for 12 months in patients who did not undergo PCI should be considered unless there are contraindications such as excessive risk of
bleeding.
IIa C
In patients with LV thrombus, anticoagulation should be administered for up to 6 months guided by repeated imaging.341–343 IIa C
In high ischaemic-risk patientse who have tolerated DAPT without a bleeding complication, treatment with DAPT in the form of ticagrelor
60 mg twice a day on top of aspirin for longer than 12 months may be considered for up to 3 years.333
IIb B
In low bleeding-risk patients who receive aspirin and clopidogrel, low-dose rivaroxaban (2.5 mg twice daily) may be considered.338 IIb B
The use of ticagrelor or prasugrel is not recommended as part of triple antithrombotic therapy with aspirin and oral anticoagulation. III C
AMI = acute myocardial infarction; CAD = coronary artery disease; DAPT = dual antiplatelet therapy; eGFR = estimated glomerular filtration rate; LV = left ventricular; PCI =
percutaneous coronary intervention; PPI = proton pump inhibitor; STEMI = ST-segment elevation myocardial infarction.
aClass of recommendation.
bLevel of evidence.
cHistory of gastrointestinal bleeding, anticoagulant therapy, chronic non-steroidal anti-inflammatory drug/corticosteroid user, and 2 or more of the following: age 65 years,
dyspepsia, gastro-oesophageal reflux disease, H. pylori infection, and chronic alcohol use.
dOral anticoagulant, aspirin, and clopidogrel.
eDefined as age 50 years, and at least one of the following additional high-risk features: age 65 years, diabetes mellitus on medication, a prior spontaneous AMI, multivessel
CAD, or chronic renal dysfunction (eGFR <60 ml/min/1.73 m2).
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received oral metoprolol within 12 h. Early i.v. metoprolol admin-
istration did not show any benefit in reducing CMR-based
infarct size, the trial primary endpoint, available only in 342
patients (55%), or the level of cardiac biomarker release. Early i.v.
metoprolol was associated with a borderline reduction of malig-
nant ventricular arrhythmias (3.6% vs. 6.9%; P = 0.050). Patients
treated with i.v. metoprolol showed no increased risk of haemo-
dynamic instability, atrioventricular (AV) block, or MACE at
30 days. Post hoc analyses from primary PCI trials testing
other hypotheses have suggested that early i.v. beta-blocker
administration might be associated with a clinical benefit, but a
selection bias cannot be excluded even after correction for imbal-
ances in baseline characteristics.351,352 Based on the current avail-
able evidence, early administration of i.v. beta-blockers at the
time of presentation followed by oral beta-blockers should
be considered in haemodynamically stable patients undergoing
primary PCI.
7.3.2 Mid- and long-term beta-blocker treatment
The benefit of long-term treatment with oral beta-blockers after
STEMI is well established, although most of the supporting data
come from trials performed in the pre-reperfusion era.353 A
recent multicentre registry enrolling 7057 consecutive patients
with AMI showed a benefit in terms of mortality reduction at a
median follow-up of 2.1 years associated with beta-blocker pre-
scription at discharge, although no relationship between dose and
outcomes could be identified.354 Using registry data, the impact of
newly introduced beta-blocker treatment on cardiovascular
events in 19 843 patients with either ACS or undergoing PCI was
studied.355 At an average of 3.7 years of follow-up, the use of beta-
blockers was associated with a significant mortality reduction
(adjusted HR 0.90, 95% CI 0.84–0.96). The association between
beta-blockers and outcomes differed significantly between
patients with and without a recent MI (HR for death 0.85 vs. 1.02;
Pint = 0.007). Opposing these results, in a longitudinal observatio-
nal propensity-matched study including 6758 patients with pre-
vious MI, beta-blocker use was not associated with a lower risk of
cardiovascular events or mortality.356 Based on the current evi-
dence, routine administration of beta-blockers in all post-STEMI
patients should be considered as discussed in detail in the heart
failure guidelines;6 beta-blockers are recommended in patients
with reduced systolic LV function (LVEF <_40%), in the absence of
contraindications such as acute heart failure, haemodynamic insta-
bility, or higher degree AV block. Agents and doses of proven effi-
cacy should be administered.357–361 As no study has properly
addressed beta-blocker duration to date, no recommendation in
this respect can be made. Regarding the timing of initiation of oral
beta-blocker treatment in patients not receiving early i.v. beta-
blockade, a retrospective registry analysis on 5259 patients sug-
gested that early (i.e. <24 h) beta-blocker administration con-
veyed a survival benefit compared with a delayed one.362
Therefore, in haemodynamically stable patients, oral beta-blocker
initiation should be considered within the first 24 h.
7.4 Lipid-lowering therapy
The benefits of statins in secondary prevention have been
unequivocally demonstrated,363 and trials have shown the benefits
of early and intensive statin therapy in ACS.364,365 A meta-analysis
of trials comparing more- vs. less-intensive LDL-C lowering with
statins indicated that more-intensive statin therapy produced
greater reductions in the risks of cardiovascular death, non-fatal
MI, ischaemic stroke, and coronary revascularization.366 For every
1.0 mmol/L reduction in LDL-C, these further reductions in risk
were similar to the proportional reductions in the trials of statins
vs. control. Therefore, statins are recommended in all patients
with AMI, irrespective of cholesterol concentration at presenta-
tion. Lipid-lowering treatment should be started as early as possi-
ble, as this increases patient adherence after discharge, and given
as high-intensity treatment, as this is associated with early and sus-
tained clinical benefits.4 The intensity of statin therapy should be
increased in those receiving a low- or moderate-intensity statin
treatment at presentation, unless they have a history of intoler-
ance to high-intensity statin therapy or other characteristics that
may influence safety.366–368 The treatment goal is an LDL-C con-
centration of < 1.8 mmol/L (<70 mg/dL) or at least 50% reduction
in LDL-C if the baseline LDL-C level is 1.8–3.5 mmol/L.4,367,369
The use of lower-intensity statin therapy should be considered in
patients at increased risk of side effects from statins (e.g. elderly,
hepatic or renal impairment, previous side effects, or a potential
for interaction with essential concomitant therapy). Following MI,
the lipid profile goes through phasic changes, with small reduc-
tions in total cholesterol, LDL-C, and HDL-C, and increases in tri-
glycerides within the first 24 h.370,371 A lipid profile should be
obtained as early as possible after admission for STEMI and can be
non-fasting, as total and HDL-C show little diurnal variation and
LDL-C variation is within 10%.372 Lipids should be re-evaluated
4–6 weeks after the ACS to determine whether the target levels
have been reached and regarding safety issues; the lipid lowering
therapy can then be adjusted accordingly. Trial results with high
doses of atorvastatin and simvastatin366,373–375 favour a high-
intensity statin.
In patients known to be intolerant of any dose of statin, treat-
ment with ezetimibe should be considered. In the Improved
Reduction of Outcomes: Vytorin Efficacy International Trial
(IMPROVE-IT), 18 144 patients with a recent ACS (29% with
STEMI) were randomized to either ezetimibe 10 mg/simvastatin
40 mg or simvastatin 40 mg alone (simvastatin was up-titrated to
80 mg if LDL-C was >79 mg/dL or 2.04 mmol/L).376 Over a period
of 7 years, the composite primary endpoint of cardiovascular
death, MI, hospital admission for unstable angina, coronary revas-
cularization, or stroke was significantly lower in the combined
treatment arm compared with the statin-only arm (32.7% vs.
34.7%; HR 0.94, 95% CI 0.89–0.99).
Recent data from phase I–III trials show that proprotein con-
vertase subtilisin/kexin type 9 (PCSK9) inhibitors decrease LDL-
C up to 60%, either as monotherapy or in addition to a statin
dose, and also have beneficial effects on triglycerides and HDL-
C.377–380 Meta-analyses of existing trials with more than 10 000
patients indicate a significant mortality benefit (HR 0.45, 95% CI
0.23–0.86) but are based on relatively few endpoints.378,381 In
the Further Cardiovascular Outcomes Research with PCSK9
Inhibition in Subjects with Elevated Risk (FOURIER) trial consist-
ing of 27 564 patients with atherosclerotic cardiovascular disease,
additional risk factors, and LDL 70 mg/dL (1.8 mmol/L), who
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..were already receiving moderate or high intensity statin therapy
as compared to placebo, evolocumab injections reduced the pri-
mary composite endpoint of cardiovascular death, MI, stroke,
hospitalization for unstable angina, or coronary revascularization
by 15% in relative rate and by 1.5% in absolute rate. There were
no differences in all-cause mortality or cardiovascular mortality
and no significant differences in adverse events.382 Given the
moderate effect over 2 years and the absence of mortality reduc-
tion, its use should still be restricted to selected high-risk
patients.
Based on this relatively limited body of evidence, clinicians should
consider adding a non-statin treatment to patients at high risk who
do not reach treatment targets after STEMI despite the maximum
tolerated dose of statin.
7.5 Nitrates
The routine use of nitrates in STEMI was of no benefit in a
randomized controlled trial against placebo and is therefore not
recommended.383 Intravenous nitrates may be useful during the
acute phase in patients with hypertension or heart failure, pro-
vided there is no hypotension, RV infarction, or use of phospho-
diesterase type 5 inhibitors in the previous 48 h. Following the
acute phase, nitrates remain valuable agents to control residual
angina symptoms.
7.6 Calcium antagonists
A meta-analysis of 17 trials involving calcium antagonists early in
the course of STEMI showed no beneficial effect on death or rein-
farction, with a trend of higher mortality for patients treated with
nifedipine. Therefore, routine use of calcium antagonists in the
acute phase is not indicated.384,385 In the chronic phase, a random-
ized controlled trial allocating 1775 patients with MI not on beta-
blockers to verapamil or placebo found that the risk of mortality
and reinfarction was reduced with verapamil.386 Thus, in patients
with contraindications to beta-blockers, particularly in the pres-
ence of obstructive airway disease, calcium antagonists are a rea-
sonable option for patients without heart failure or impaired LV
function. Routine use of dihydropyridines, on the other hand, has
failed to show benefit after STEMI,387 and they should therefore
only be prescribed for clear additional indications such as hyper-
tension or residual angina.388
7.7 Angiotensin-converting enzyme
inhibitors and angiotensin II receptor
blockers
ACE inhibitors are recommended in patients with an impaired
LVEF (<_40%) or who have experienced heart failure in the early
phase.383,389–392 A systematic overview of trials of ACE inhibition
early in STEMI indicated that this therapy is safe, well tolerated,
and associated with a small but significant reduction in 30-day
mortality, with most of the benefit observed in the first
week.383,393 Treatment with ACE inhibitors is recommended in
patients with systolic LV dysfunction or heart failure, hyperten-
sion, or diabetes, and should be considered in all STEMI
patients.394,395 Patients who do not tolerate an ACE inhibitor
should be given an angiotensin II receptor blocker (ARB). In the
context of STEMI, valsartan was found to be non-inferior to cap-
topril in the VALsartan In Acute myocardial iNfarcTion
(VALIANT) trial.396
7.8 Mineralocorticoid/aldosterone
receptor antagonists
Mineralocorticoid receptor antagonist (MRA) therapy is recom-
mended in patients with LV dysfunction (LVEF <_40%) and heart
failure after STEMI.397–400 Eplerenone, a selective aldosterone
receptor antagonist, has been shown to reduce morbidity and
mortality in these patients. The Eplerenone Post-AMI Heart fail-
ure Efficacy and SUrvival Study (EPHESUS) randomized 6642
post-MI patients with LV dysfunction (LVEF <_40%) and symptoms
of heart failure/diabetes to eplerenone or placebo within 3–14
days after their infarction.397 After a mean follow-up of 16 months,
there was a 15% relative reduction in total mortality and a 13%
reduction in the composite of death and hospitalization for cardi-
ovascular events.
Two recent studies have indicated a beneficial effect of early
treatment with MRA in the setting of STEMI without heart failure.
The Double-Blind, Randomized, Placebo-Controlled Trial
Evaluating The Safety And Efficacy Of Early Treatment With
Eplerenone In Patients With Acute Myocardial Infarction
(REMINDER) trial randomized 1012 patients with acute STEMI
without heart failure to eplerenone or placebo within 24 h of
symptom onset.401 After 10.5 months, the primary combined end-
point [CV mortality, re-hospitalization, or extended initial hospital
stay due to diagnosis of heart failure, sustained ventricular tachy-
cardia or fibrillation, ejection fraction <_40%, or elevated B-type
natriuretic peptide (BNP)/N-terminal pro B-type natriuretic pep-
tide (NT-proBNP)] occurred in 18.2% of the active group vs.
29.4% in the placebo group (P < 0.0001), with the difference pri-
marily driven by BNP levels.401 The Aldosterone Lethal effects
Blockade in Acute myocardial infarction Treated with or without
Reperfusion to improve Outcome and Survival at Six months
follow-up (ALBATROSS) trial randomized 1603 patients with
acute STEMI or high-risk NSTEMI to a single i.v. bolus of potassium
canrenoate (200 mg) followed by spironolactone (25 mg daily) vs.
placebo. Overall, the study found no effect on the composite out-
come (death, resuscitated cardiac arrest, significant ventricular
arrhythmia, indication for implantable defibrillator, or new or
worsening heart failure) at 6 months. In an exploratory analysis of
the STEMI subgroup (n = 1229), the outcome was significantly
reduced in the active treatment group (HR 0.20, 95% CI
0.06–0.70).402 Future studies will clarify the role of MRA treat-
ment in this setting.
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When using MRA, care should be taken with reduced renal func-
tion [creatinine concentration >221 mmol/L (2.5 mg/dL) in men and
>177 mmol/L (2.0 mg/dL) in women] and routine monitoring of
serum potassium is warranted.
Figures 5 and 6 present the mostly prescribed interventions
(class I and IIa) in patients undergoing primary PCI or fibrinolysis
strategies.
8. Complications following ST-
segment elevation myocardial
infarction
Expanded information about complications following STEMI is pre-
sented in the Web Addenda.
Routine therapies in the acute, subacute, and long-term phases: beta-blockers, angiotensin-converting enzyme
inhibitors, angiotensin II receptor blockers, mineralocorticoid receptor antagonists, and lipid-lowering treatments
after ST-elevation myocardial infarction
Recommendations Classa Levelb
Beta-blockers
Oral treatment with beta-blockers is indicated in patients with heart failure and/or LVEF <_40% unless contraindicated.357–361 I A
Intravenous beta-blockers should be considered at the time of presentation in patients undergoing primary PCI without con-
traindications, with no signs of acute heart failure, and with an SBP >120 mmHg.346–348,350,403
IIa A
Routine oral treatment with beta-blockers should be considered during hospital stay and continued thereafter in all patients
without contraindications.344,354–356,404,405
IIa B
Intravenous beta-blockers must be avoided in patients with hypotension, acute heart failure or AV block, or severe
bradycardia.344
III B
Lipid lowering therapies
It is recommended to start high-intensity statin therapyc as early as possible, unless contraindicated, and maintain it long-
term.364,366,368
I A
An LDL-C goal of < 1.8 mmol/L (70 mg/dL) or a reduction of at least 50% if the baseline LDL-C is between 1.8–3.5 mmol/L
(70–135 mg/dL) is recommended.367,369,376,382
I B
It is recommended to obtain a lipid profile in all STEMI patients as soon as possible after presentation.369,406 I C
In patients with LDL-C 1.8 mmol/L (70 mg/dL) despite a maximally tolerated statin dose who remain at high risk, further
therapy to reduce LDL-C should be considered.376,382
IIa A
ACE inhibitors/ARBs
ACE inhibitors are recommended, starting within the first 24 h of STEMI in patients with evidence of heart failure, LV systolic
dysfunction, diabetes, or an anterior infarct.383
I A
An ARB, preferably valsartan, is an alternative to ACE inhibitors in patients with heart failure and/or LV systolic dysfunction,
particularly those who are intolerant of ACE inhibitors.396,407
I B
ACE inhibitors should be considered in all patients in the absence of contraindications.394,395 IIa A
MRAs
MRAs are recommended in patients with an LVEF <_40% and heart failure or diabetes, who are already receiving an ACE inhib-
itor and a beta-blocker, provided there is no renal failure or hyperkalaemia.397 I B
AV = atrioventricular; ACE = angiotensin-converting enzyme; ARB = angiotensin II receptor blocker; LDL-C = low-density lipoprotein cholesterol; LV = left ventricular; LVEF
= left ventricular ejection fraction; MRA = mineralocorticoid receptor antagonist; PCI = percutaneous coronary intervention; SBP = systolic blood pressure; STEMI = ST-seg-
ment elevation myocardial infarction.
aClass of recommendation.
bLevel of evidence.
cHigh-intensity statin defined as atorvastatin 40–80 mg and rosuvastatin 20–40 mg.
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Figure 5 “Do not forget” interventions in STEMI patients undergoing a primary PCI strategy. ACE = angiotensin-converting enzyme; DAPT = dual
antiplatelet therapy; DES = drug eluting stent; ECG = electrocardiogram; echo = echocardiogram; ED = emergency department; HF = heart failure;
i.v. = intravenous; IRA = infarct related artery; LVEF = left ventricular ejection fraction; MRA = mineralcorticoid receptor antagonist; PCI = percuta-
neous coronary intervention; STEMI = ST-segment elevation myocardial infarction; UFH = Unfractionated heparin.
Mostly prescribed interventions (class I, green, and IIa, yellow) are presented along with the expected timing of delivery. Solid lines represent recur-
rent (daily) intervention. Double-arrowed dashed lines represent a time-window in which the intervention can be delivered.
1Aspirin loading dose: 150–300 mg chewed or 75–250 mg intravenous (in patients not already on an aspirin maintenance dose).
2Prasugrel loading dose: 60 mg. Ticagrelor loading dose: 180 mg. If there are contra-indications for prasugrel/ticagrelor or these are not
available, a loading dose of clopidogrel (600 mg) is indicated.
3If the interventional cardiologist is not expert in radial access, the femoral route is then preferred.
4Enoxaparin or bivalirudin are alternatives to unfractionated heparin (Class IIa A).
5Aspirin maintenance dose: 75–100 mg oral.
6Prasugrel maintenance dose: 10 mg once daily. Ticagrelor maintenance dose: 90 mg twice daily. If there are contra-indications for pra-
sugrel/ticagrelor or these are not available, clopidogrel maintenance (75 mg daily) is indicated.
a90 min represents the maximum target time to PCI-mediated reperfusion. For patients presenting in a PCI-centre, this target time is
60 min.
bProlongation of ticagrelor (60 mg twice daily) in addition to aspirin may be considered for up to 36 months in patients at high ischaemic
risk who have tolerated DAPT without a bleeding complication.
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Figure 6 “Do not forget” interventions in STEMI patients undergoing a successful fibrinolysis strategy. ACE = angiotensin-converting enzyme;
DAPT = dual antiplatelet therapy; DES = drug eluting stent; ECG = electrocardiogram; echo = echocardiogram; HF = heart failure; i.v. = intravenous;
IRA = infarct related artery; LVEF = left ventricular ejection fraction; MRA = mineralcorticoid receptor antagonist; PCI = percutaneous coronary
intervention; STEMI = ST-segment elevation myocardial infarction; UFH = Unfractionated heparin.
Mostly prescribed interventions (class I, green, and IIa, light yellow) are presented along with the expected timing of delivery. Solid lines represent
recurrent (daily) intervention. Double-arrowed dashed lines represent a time-window in which the intervention can be delivered.
1Enoxaparin dose: 30 mg i.v. bolus followed by 1 mg/kg subcutaneous every 12 hours (dose adjustment for 75 years and renal insuffi-
ciency is presented in Table 9). Unfractionated heparin is an alternative to enoxaparin.
2Aspirin loading dose: 150–300 mg chewed or 75–250 mg intravenous.
3Clopidogrel loading dose: 300 mg oral (75 mg in 75 years).
4Aspirin maintenance dose: 75–100 mg oral
5Clopidogrel maintenance therapy: 75 mg daily.
648 hours after fibrinolysis, switch to prasugrel/ticagrelor may be considered in PCI-treated patients.
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8.1 Myocardial dysfunction
8.1.1 Left ventricular dysfunction
See Web Addenda.
8.1.2 Right ventricular involvement
See Web Addenda.
8.2 Heart failure
8.2.1 Clinical presentations
See Web Addenda.
8.2.2 Management
Patients with heart failure should be under continuous monitoring
of heart rhythm, blood pressure, and urinary output. The mecha-
nism of heart failure should be assessed early by physical examina-
tion, ECG, echocardiography, and (when not rapidly controlled)
with invasive haemodynamic monitoring, and corrected as soon as
possible.
Patients with pulmonary congestion and SaO2 <90% or partial
pressure of oxygen (PaO2) <60 mmHg (8.0 kPa) require oxygen
therapy and SaO2 monitoring to correct hypoxaemia, with a tar-
get of 95%, and may require periodic blood-gas assessment. Initial
pharmacological treatment includes i.v. loop diuretics (e.g. furose-
mide 20–40 mg i.v. with repeated doses at intervals as needed
according to clinical evolution and diuresis) and, if blood pressure
allows it, i.v. nitrates, avoiding hypotension or excessive falls in
blood pressure. The early use of beta-blockers, ACE inhibitors/
ARBs, and MRA is recommended in the absence of hypotension,
hypovolaemia, or renal dysfunction. Causal treatment is essential.
Coronary revascularization should be performed early when sig-
nificant CAD is still present. Rhythm disturbances, valvular dys-
function, and hypertension should be corrected as soon as
possible. Hypertension should be treated promptly with oral ACE
inhibitors/ARBs and i.v. nitrates. In very severe cases, sodium
nitroprusside infusion may be necessary. Persistent myocardial
ischaemia should be treated with early coronary revascularization.
Atrial and ventricular dysrhythmias, and valvular dysfunction or
Recommendations for the management of left ventricular dysfunction and acute heart failure in ST-elevation myocar-
dial infarction
Recommendations Classa Levelb
ACE inhibitor (or if not tolerated, ARB) therapy is indicated as soon as haemodynamically stable for all patients with
evidence of LVEF <_40% and/or heart failure to reduce the risk of hospitalization and death.390,396,412,413
I A
Beta-blocker therapy is recommended in patients with LVEF <_40% and/or heart failure after stabilization, to reduce the risk
of death, recurrent MI, and hospitalization for heart failure.358–361,414–416
I A
An MRA is recommended in patients with heart failure and LVEF <_40% with no severe renal failure or hyperkalaemia to reduce
the risk of cardiovascular hospitalization and death.397
I B
Loop diuretics are recommended in patients with acute heart failure with symptoms/signs of fluid overload to improve
symptoms.
I C
Nitrates are recommended in patients with symptomatic heart failure with SBP >90 mmHg to improve symptoms and
reduce congestion.
I C
Oxygen is indicated in patients with pulmonary oedema with SaO2 <90% to maintain a saturation >95%. I C
Patient intubation is indicated in patients with respiratory failure or exhaustion, leading to hypoxaemia, hypercapnia, or acidosis,
and if non-invasive ventilation is not tolerated.
I C
Non-invasive positive pressure ventilation (continuous positive airway pressure, biphasic positive airway pressure) should
be considered in patients with respiratory distress (respiratory rate >25 breaths/min, SaO2 <90%) without
hypotension.410,411,417–419
IIa B
Intravenous nitrates or sodium nitroprusside should be considered in patients with heart failure and elevated SBP to control
blood pressure and improve symptoms.
IIa C
Opiates may be considered to relieve dyspnoea and anxiety in patients with pulmonary oedema and severe dyspnoea.
Respiration should be monitored.6,408
IIb B
Inotropic agents may be considered in patients with severe heart failure with hypotension refractory to standard medical
treatment. IIb C
ACE = angiotensin-converting enzyme; ARB = angiotensin II receptor blocker; LV = left ventricular; LVEF = left ventricular ejection fraction; MRA = mineralocorticoid receptor
antagonist; SaO2 = arterial oxygen saturation; SBP = systolic blood pressure; STEMI = ST-segment elevation myocardial infarction.
aClass of recommendation.
bLevel of evidence.
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..mechanical complications, should be treated as appropriate (see
specific sections in this document).
Severely symptomatic patients with pulmonary congestion may
also need i.v. morphine to reduce dyspnoea and anxiety, but rou-
tine use is not recommended due to concerns about its safety, as
it may induce nausea and hypopnea.408,409 Non-invasive positive
pressure ventilation (continuous positive airway pressure, bipha-
sic positive airway pressure) or high-flow nasal cannula is effective
in treating pulmonary oedema and should be considered in
patients with respiratory distress (respiratory rate >25 breaths/
min, SaO2 <90%) and started soon.
410,411 Endotracheal intubation
and ventilatory support may be required in patients unable to
achieve adequate oxygenation, or in those with excess respiratory
work or evidence of hypercapnia due to respiratory exhaustion.
Ultrafiltration to reduce fluid overload may be considered in
patients who are refractory to diuretics, especially in patients with
hyponatraemia.
In patients with heart failure and adequate blood pressure
(SBP >90 mmHg), but a severe reduction in cardiac output resulting
in compromised vital organ perfusion not responding to standard
therapy, treatment with dobutamine or levosimendan may
be considered. However, the clinical evidence of levosimendan in
cardiogenic shock is limited. Further details on the management
of acute heart failure can be found in the 2016 ESC Guidelines
for the diagnosis and treatment of acute and chronic heart failure.6
8.2.2.1 Management of hypotension
In patients with hypotension and normal perfusion without evidence
of congestion or volume overload (i.e. collapsible inferior vena cava),
gentle volume loading should be attempted after ruling out complica-
tions such as mechanical or severe mitral regurgitation, with central
pressure monitoring. Bradycardia or tachyarrhythmias should be cor-
rected or controlled. In patients with RV infarction, volume overload-
ing should be avoided because it might worsen haemodynamics.420
If hypotension persists, inotropic therapy, preferably with dobut-
amine, may be considered.420
8.2.2.2 Management of cardiogenic shock
Cardiogenic shock is defined as persistent hypotension (SBP
<90 mmHg) despite adequate filling status with signs of hypoperfu-
sion. It complicates 6–10% of all STEMI cases and remains a leading
cause of death, with in-hospital mortality rates50%.421 Shock is also
considered to be present if i.v. inotropes and/or mechanical support
are needed to maintain an SBP >90 mmHg. In STEMI patients present-
ing with cardiogenic shock in which PCI-mediated reperfusion is esti-
mated to occur >120 min, immediate fibrinolysis and transfer to a PCI
centre should be considered. In these cases, upon arrival at the PCI
centre, emergent angiography is indicated, regardless of the
ST resolution and the time from fibrinolysis administration. It is usually
associated with extensive LV damage, but may occur in RV infarction.
Cardiogenic shock characterization and management do not necessa-
rily need invasive haemodynamic monitoring, but ventricular and valve
function should be urgently evaluated by transthoracic echocardiogra-
phy and associated mechanical complications ruled out.422–426
The first step in patients with cardiogenic shock is to identify
the mechanism and to correct any reversible cause such as hypo-
volaemia, drug-induced hypotension, or arrhythmias; alternatively,
initiate the treatment of potential specific causes, such as mechani-
cal complications or tamponade.
Treatments include immediate reperfusion, with primary PCI
whenever possible,248,427 and complete revascularisation if multives-
sel disease is present. In addition, patients at the highest risk for devel-
opment of shock might benefit from an early transfer to tertiary
centres before the onset of haemodynamic instability.
Antithrombotic therapy does not differ from that in any STEMI
patient. The specificities of the management of low-output cardio-
genic shock associated with RV infarction are mentioned in the Web
Addenda.
Invasive monitoring with an arterial line is recommended.6 A
pulmonary artery catheter may be considered, in order to per-
form a careful adjustment of filling pressures and assessment of
cardiac output or in cases of shock of unexplained cause.
Hypovolaemia should be ruled out first and corrected with fluid
loading. Pharmacological therapy aims to improve organ perfusion
by increasing cardiac output and blood pressure. Diuretic therapy
is recommended when adequate perfusion is attained.
Intravenous inotropic agents or vasopressors are usually required
to maintain an SBP >90 mmHg, and to increase cardiac output and
improve vital organ perfusion. Dobutamine is the initial therapy
for patients with predominant low cardiac output, whereas nore-
pinephrine may be safer and more effective than dopamine in
patients with cardiogenic shock and severe hypotension.428
Levosimendan may be considered as an alternative, especially
for patients on chronic beta-blocker therapy, because its
inotropic effect is independent of beta-adrenergic stimulation.
Phosphodiesterase III inhibitors are not recommended in STEMI
patients.
IABP counterpulsation does not improve outcomes in patients
with STEMI and cardiogenic shock without mechanical complica-
tions,177 nor does it significantly limit infarct size in those with
potentially large anterior MIs.175 Therefore, routine IABP coun-
terpulsation cannot be recommended, but may be considered for
haemodynamic support in selected patients (i.e. severe mitral
insufficiency or ventricular septal defect). A small exploratory trial
studying the Impella CP percutaneous circulatory support device
did not find any benefit compared with IABP in AMI complicated
by cardiogenic shock.429
Mechanical LV assist devices (LVADs), including percutaneous
short-term mechanical circulatory support devices (i.e. intra-cardiac
axial flow pumps and arterial-venous extracorporeal membrane oxy-
genation), have been used in patients not responding to standard
therapy, including inotropes, fluids, and IABP, but evidence regarding
their benefits is limited.430 Therefore, short-term mechanical
circulatory support may be considered as a rescue therapy in order
to stabilize the patients and preserve organ perfusion (oxygenation)
as a bridge to recovery of myocardial function, cardiac transplanta-
tion, or even LV assist device destination therapy on an individual
basis.431,432
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8.3 Management of arrhythmias and
conduction disturbances in the acute
phase
Arrhythmias and conduction disturbances are common during the
early hours of STEMI and are also important prognostic factors.438
Despite increased awareness and improved basic and advanced life
support, the incidence of sudden cardiac death, mainly due to fast
ventricular tachycardia (VT) and VF in the pre-hospital phase,
remains high.438,439 Early reperfusion therapy reduces the risk of ven-
tricular arrhythmias and cardiovascular death.440,441 The presence of
life-threatening arrhythmias requires an urgent need for a fast and
complete revascularization in STEMI.438,442 The evidence for benefits
of antiarrhythmic drugs in STEMI patients is limited and negative
effects of antiarrhythmic drugs on early mortality have been demon-
strated.439 Careful use of antiarrhythmic drugs is generally recom-
mended and alternative treatment options such as electrical
cardioversion, a ‘wait and see’ strategy for arrhythmias with no or
moderate haemodynamic relevance, or in selected cases cardiac pac-
ing and catheter ablation, should be considered. Correction of elec-
trolyte imbalances and early treatment with beta-blockers, ACE
inhibitors/ARBs, and statins is recommended.438,443
8.3.1 Supraventricular arrhythmias
The most frequent supraventricular arrhythmia is AF, with up to
21% of STEMI patients affected.444 AF may be pre-existing, first-
time detected, or of new onset. Patients with AF have more
comorbidities and are at higher risk for complications.445 In many
cases, the arrhythmia is well tolerated and no specific treatment is
required, other than anticoagulation.5 Prompt treatment is
required in acute haemodynamic instability. There is scarce infor-
mation indicating preferences for rate control over rhythm control
in this situation.446 Electrical cardioversion should be considered
but early recurrence of AF is frequent after successful cardiover-
sion. Acute rhythm control with antiarrhythmic drugs is limited to
the use of amiodarone.5,444 Adequate rate control can be accom-
plished by administration of beta-blockers.438,446 In patients with
extensive myocardial damage or severe LV dysfunction, rate con-
trol is more safely achieved with i.v. digoxin with or without con-
comitant administration of i.v. amiodarone. When co-
administering i.v. digoxin and amiodarone, close monitoring for
digoxin toxicity is necessary as digoxin serum concentrations may
be increased. Several, but not all, studies have suggested that new-
onset AF may be reduced by beta-blockers, ACE inhibitors/ARBs,
and also early-onset statin therapy.444 Patients with AF and risk fac-
tors for thromboembolism should be adequately treated with
chronic oral anticoagulation.5 STEMI patients with documented AF
have worse short- and long-term prognoses when compared with
patients in sinus rhythm.445,447 Presence of AF is associated with a
higher reinfarction rate, higher stroke rate, higher risk for heart fail-
ure, and may also increase the risk for sudden cardiac
death.444,445,448 Of note, also transient, self-terminating AF during
STEMI relates to a significantly higher stroke rate during long-term
follow-up.445,448
Recommendations for the management of cardio-
genic shock in ST-elevation myocardial infarction
Recommendations Classa Levelb
Immediate PCI is indicated for patients with
cardiogenic shock if coronary anatomy is
suitable. If coronary anatomy is not suitable
for PCI, or PCI has failed, emergency CABG
is recommended.248
I B
Invasive blood pressure monitoring with an
arterial line is recommended.
I C
Immediate Doppler echocardiography is
indicated to assess ventricular and valvular
functions, loading conditions, and to detect
mechanical complications.
I C
It is indicated that mechanical complications
are treated as early as possible after discus-
sion by the Heart Team.
I C
Oxygen/mechanical respiratory support is
indicated according to blood gases.
I C
Fibrinolysis should be considered in patients
presenting with cardiogenic shock if a pri-
mary PCI strategy is not available within
120 min from STEMI diagnosis and mechani-
cal complications have been ruled out.
IIa C
Complete revascularization during the index
procedure should be considered in patients
presenting with cardiogenic shock.
IIa C
Intra-aortic balloon pumping should be con-
sidered in patients with haemodynamic
instability/cardiogenic shock due to mechan-
ical complications.
IIa C
Haemodynamic assessment with pulmonary
artery catheter may be considered for con-
firming diagnosis or guiding therapy.433
IIb B
Ultrafiltration may be considered for
patients with refractory congestion, who
failed to respond to diuretic-based
strategies.434–436
IIb B
Inotropic/vasopressor agents may be con-
sidered for haemodynamic stabilization.
IIb C
Short-term mechanical supportc may be
considered in patients in refractory shock.
IIb C
Routine intra-aortic balloon pumping is not
indicated.177,437 III B
CABG = coronary artery bypass graft surgery; ECLS = extracorporeal life sup-
port; ECMO = extracorporeal membrane oxygenation; PCI = percutaneous cor-
onary intervention; STEMI = ST-segment elevation myocardial infarction.
aClass of recommendation.
bLevel of evidence.
cPercutaneous cardiac support devices, ECLS, and ECMO.
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.. 8.3.2 Ventricular arrhythmias
The incidence of VT and VF has declined over recent decades,
most probably due to the uptake of reperfusion strategies and the
early use of beta-blockers.3 However, 6–8% of patients still
develop haemodynamically significant VT or VF during this
phase.439 The typical arrhythmia presentation is unstable, fre-
quently polymorphic, and relatively fast VT, often degenerating
into VF. Urgent reperfusion is most important as ischaemia often
triggers these arrhythmias.72 Beta-blockers are recommended if no
contraindications exist.346,347,350,454 Repetitive electrical cardiover-
sion or defibrillation may be necessary.455 If there is no sufficient
control, i.v. administration of amiodarone is recommended.439,456
In case of contraindications to amiodarone, i.v. lidocaine may be
considered, although no studies comparing superiority of
either drug in STEMI patients are available. The prognostic role of
early VT/VF within the first 48 h of STEMI is still controversial.
Available data suggest that patients with early VT/VF have
increased 30-day mortality but no increased long-term arrhythmic
risks.442,457,458
VT or VF may occur at the time of restoration of coronary blood
flow (reperfusion arrhythmias). No specific antiarrhythmic drug
therapy is necessary due to the benign long-term course.
Ventricular premature beats are very frequent on the first day of
the acute phase and complex arrhythmias (multiform complexes,
short runs, or the R-on-T phenomenon) are common. Their value
as predictors of VF is questionable and no specific therapy is
required. Sustained VT or VF outside the early phase (usually 48 h
after STEMI onset) not triggered by recurrent ischaemia has a poor
prognostic implication, and evaluation for ICD implantation for sec-
ondary prevention of sudden cardiac death is recommended
according to current guidelines.3 Primary prevention of sudden car-
diac death with the ICD within 40 days after MI in the absence of
VT/VF is generally not indicated.3 Patients should be re-evaluated
for ICD implantation 6–12 weeks after revascularization, although
those with pre-existing impaired LVEF may be considered for ICD
implantation for primary prevention even within the early post-
infarction period.3,438
Some patients may develop electrical storm and/or incessant VT
despite complete revascularization and treatment with antiarrhyth-
mic drugs. Overdrive stimulation may help to control this situation;
however, recurrence of VT/VF upon cessation of stimulation is fre-
quent and catheter ablation of such triggers appears to be the only
treatment option. Successful radiofrequency ablation has been
shown to abolish recurrent VT/VF.459–461
Management of atrial fibrillation
Recommendations Classa Levelb
Acute rate control of AF
Intravenous beta-blockers are indicated for
rate control if necessary and there are no
clinical signs of acute heart failure or
hypotension.449
I C
Intravenous amiodarone is indicated for rate
control if necessary in the presence of con-
comitant acute heart failure and no
hypotension.450
I C
Intravenous digitalis should be considered
for rate control if necessary in the presence
of concomitant acute heart failure and
hypotension.451
IIa B
Cardioversion
Immediate electrical cardioversion is indi-
cated when adequate rate control cannot
be achieved promptly with pharmacological
agents in patients with AF and ongoing
ischaemia, severe haemodynamic compro-
mise, or heart failure.
I C
Intravenous amiodarone is indicated to pro-
mote electrical cardioversion and/or
decrease risk for early recurrence of AF
after electrical cardioversion in unstable
patients with recent onset AF.
I C
In patients with documented de novo AF
during the acute phase of STEMI, long-term
oral anticoagulation should be considered
depending on CHA2DS2-VASc score and
taking concomitant antithrombotic therapy
into account.5,444
IIa C
Digoxin is ineffective in converting recent
onset AF to sinus rhythm and is not indi-
cated for rhythm control.452,453
III A
Calcium channel blockers and beta-blockers
including sotalol are ineffective in converting
recent onset AF to sinus rhythm.453
III B
Prophylactic treatment with antiarrhythmic
drugs to prevent AF is not indicated.438,444
III B
AF = atrial fibrillation; CHA2DS2-VASc = Cardiac failure, Hypertension, Age 75
(Doubled), Diabetes, Stroke (Doubled) – VAScular disease, Age 65–74 and Sex
category (Female); STEMI = ST-segment elevation myocardial infarction.
aClass of recommendation.
bLevel of evidence.
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8.3.3 Sinus bradycardia and atrioventricular block
Sinus bradycardia is common in the first hours of STEMI, especially in
inferior MI. In some cases, opioids are responsible.468 It often
requires no treatment. If accompanied by severe hypotension, sinus
bradycardia should be treated with i.v. atropine. Second-degree type
I (Mobitz I or Wenckebach) AV block is usually associated with infe-
rior wall MI and seldom causes adverse haemodynamic effects. If so,
atropine should be used first; if it fails, pacing should be instituted.
Agents that slow AV conduction (such as beta-blockers, digitalis,
verapamil, or amiodarone) should be used with caution. Second-
degree type II (Mobitz II) AV block and complete AV block may be
indications for pacing. AV sequential pacing should be considered in
patients with complete AV block, RV infarction, and haemodynamic
compromise. Revascularization should be considered in patients with
AV block who have not yet received reperfusion therapy (e.g. late
arrival).
AV block associated with inferior wall infarction is usually supra-
Hisian and usually resolves spontaneously or after reperfusion. AV
block associated with anterior wall MI is usually infra-Hisian and has a
high mortality rate due to the extensive myocardial necrosis. The
development of a new bundle branch block or hemiblock usually indi-
cates extensive anterior MI. A transvenous pacing electrode should
be inserted in the presence of advanced AV block with a low escape
rhythm, as described above, and considered if bifascicular or trifascic-
ular block develops. Indications for pacing are outlined in detail in the
ESC Guidelines for cardiac pacing and cardiac resynchronization
therapy.469
Management of ventricular arrhythmias and conduc-
tion disturbances in the acute phase
Recommendations Classa Levelb
Intravenous beta-blocker treatment is indicated
for patients with polymorphic VT and/or VF unless
contraindicated.462,463
I B
Prompt and complete revascularization is recom-
mended to treat myocardial ischaemia that may
be present in patients with recurrent VT and/or
VF71,72
I C
Intravenous amiodarone is recommended for
treatment of recurrent polymorphic VT.3
I C
Correction of electrolyte imbalances (especially
hypokalaemia and hypomagnesemia) is recom-
mended in patients with VT and/or VF.3
I C
In cases of sinus bradycardia with haemodynamic
intolerance or high degree AV block without
stable escape rhythm:
 i.v. positive chronotropic medication (epinephrine,
vasopressin, and/or atropine) is indicated
I C
 temporary pacing is indicated in cases of failure to
respond to positive chronotropic medication
I C
 urgent angiography with a view to revasculariza-
tion is indicated if the patient has not received pre-
vious reperfusion therapy.
I C
Intravenous amiodarone should be considered for
recurrent VT with haemodynamic intolerance
despite repetitive electrical cardioversion.438
IIa C
Transvenous catheter pace termination and/or
overdrive pacing should be considered if VT can-
not be controlled by repetitive electrical
cardioversion.
IIa C
Radiofrequency catheter ablation at a specialized
ablation centre followed by ICD implantation
should be considered in patients with recurrent
VT, VF, or electrical storm despite complete
revascularization and optimal medical therapy.
IIa C
Recurrent VT with haemodynamic repercussion
despite repetitive electrical cardioversion may be
treated with lidocaine if beta-blockers, amiodar-
one, and overdrive stimulation are not effective/
applicable.438
IIb C
Prophylactic treatment with antiarrhythmic drugs
is not indicated and may be harmful.464,465
III B
Asymptomatic and haemodynamically irrelevant
ventricular arrhythmias should not be treated
with antiarrhythmic drugs.
III C
AV = atrioventricular; i.v. = intravenous; ICD = implantable cardioverter defibril-
lator; VF = ventricular fibrillation; VT = ventricular tachycardia.
aClass of recommendation.
bLevel of evidence.
Long-term management of ventricular arrhythmias
and risk evaluation for sudden death
Recommendations Classa Levelb
ICD therapy is recommended to reduce sudden
cardiac death in patients with symptomatic heart
failure (NYHA class II–III) and LVEF <_35% despite
optimal medical therapy for >3 months and
6 weeks after MI, who are expected to survive
for at least 1 year with good functional
status.3,466,467
I A
ICD implantation or temporary use of a wearable
cardioverter defibrillator may be considered <40
days after MI in selected patients (incomplete
revascularization, pre-existing LVEF dysfunction,
occurrence of arrhythmias >48 h after STEMI
onset, polymorphic VT or VF).
IIb C
ICD = implantable cardioverter defibrillator; LVEF = left ventricular ejection frac-
tion; MI = myocardial infarction; NYHA = New York Heart Association; STEMI =
ST-segment elevation myocardial infarction; VF = ventricular fibrillation; VT =
ventricular tachycardia.
aClass of recommendation.
bLevel of evidence.
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8.4 Mechanical complications
Mechanical complications may occur in the first days following
STEMI, although incidence has fallen significantly in the era of primary
PCI. Mechanical complications are life-threatening and need prompt
detection and management. Sudden hypotension, recurrence of
chest pain, new cardiac murmurs suggestive of mitral regurgitation or
ventricular septal defect, pulmonary congestion, or jugular vein dis-
tension should raise suspicion. Immediate echocardiographic assess-
ment is needed when mechanical complications are suspected. A full
section describing mechanical complications can be found in the
Web Addenda.
8.4.1 Free wall rupture
See Web Addenda.
8.4.2 Ventricular septal rupture
See Web Addenda.
8.4.3 Papillary muscle rupture
See Web Addenda.
8.5 Pericarditis
Three major pericardial complications may occur: early infarct-
associated pericarditis, late pericarditis or post-cardiac injury
(Dressler syndrome), and pericardial effusion. These are expanded
upon in the Web Addenda.
8.5.1 Early and late (Dressler syndrome)
infarct-associated pericarditis
See Web Addenda.
8.5.2 Pericardial effusion
See Web Addenda.
9. Myocardial infarction with
non-obstructive coronary arteries
A sizeable proportion of MIs, ranging between 1–14%, occur in the
absence of obstructive (>50% stenosis) CAD.10,11 The demonstra-
tion of non-obstructive (<50%) CAD in a patient presenting with
symptoms suggestive of ischaemia and ST-segment elevation or
equivalent does not preclude an atherothrombosis aetiology, as
thrombosis is a very dynamic phenomenon and the underlying athe-
rosclerotic plaque can be non-obstructive.
The diagnostic criteria of MINOCA are presented in Table 10.
MINOCA is a working diagnosis and should lead the treating physician
to investigate underlying causes. Failure to identify the underlying cause
may result in inadequate and inappropriate therapy in these patients.
The description of the pathophysiology of the different aetiological
entities leading to MINOCA is beyond the scope of the present
document, and has been extensively described and defined in posi-
tion papers from the ESC12 and in dedicated review papers.10,11
MINOCA patients can fulfil the criteria for both MI type 1 and type 2
according to the universal definition of MI.8 There are disparate aeti-
ologies causing MINOCA and they can be grouped into: (1)
secondary to epicardial coronary artery disorders (e.g. atheroscler-
otic plaque rupture, ulceration, fissuring, erosion, or coronary dissec-
tion with non-obstructive or no CAD) (MI type 1); (2) imbalance
between oxygen supply and demand (e.g. coronary artery spasm and
coronary embolism) (MI type 2); (3) coronary endothelial dysfunc-
tion (e.g. microvascular spasm) (MI type 2); and (4) secondary to
myocardial disorders without involvement of the coronary arteries
(e.g. myocarditis470 or Takotsubo syndrome). The last two entities
may mimic MI but are better classified as myocardial injury condi-
tions. The identification of the underlying cause of MINOCA should
lead to specific treatment strategies. Although the outcome of
MINOCA strongly depends on the underlying cause, its overall prog-
nosis is serious, with a 1 year mortality of about 3.5%.10
To determine the cause of MINOCA, the use of additional diag-
nostic tests beyond coronary angiography is recommended. In gen-
eral, after ruling out obstructive CAD in a patient presenting with
STEMI, an LV angiogram or echocardiography should be considered
in the acute setting to assess wall motion or pericardial effusion. In
addition, if any of the possible aetiologies described above is sus-
pected, additional diagnostic tests may be considered.
CMR is a very helpful imaging technique due to its unique non-
invasive tissue characterization, allowing the identification of wall
motion abnormalities, presence of oedema, and myocardial scar/fib-
rosis presence and pattern. Performance of CMR within 2 weeks
after onset of symptoms should be considered to increase the diag-
nostic accuracy of the test for identifying the aetiological cause of
MINOCA.471–473
10. Assessment of quality of care
There is a wide practice gap between optimal and actual care
for patients with STEMI in hospitals around the world.474,475 To
reduce this gap and improve quality of care, it is recommended that
STEMI networks and their individual components establish measura-
ble quality indicators, systems to measure and compare these indica-
tors, perform routine audits, and implement strategies to ensure that
every patient with STEMI receives the best possible care according
to accepted standards and has the best possible outcomes
Table 10 Diagnostic criteria for myocardial infarction
with non-obstructive coronary arteries (adapted from
Agewall et al12)
AMI = acute myocardial infarction; IRA = infarct-related artery; MINOCA = myo-
cardial infarction with non-obstructive coronary arteries.
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Figure 7 Diagnostic test flow chart in MINOCA. CMR = Cardiac Magnetic Resonance; IVUS = IntraVascular UltraSound; LV = Left Ventricle;
MINOCA = Myocardial Infarction with Non-Obstructed Coronary Arteries; OCT = Optical Coherence Tomography; STEMI = ST segment
Elevation Myocardial Infarction; TOE = Trans-Oesofageal Echocardiography; TTE = Trans-Thoracic Echocardiography. Takotsubo syndrome cannot
be diagnosed with certainty in the acute phase as the definition requires follow up imaging to document recovery of left ventricular function. IVUS
and OCT frequently show more atherosclerotic plaque than may be appreciated on angiography. They also increase sensitivity for dissection. If intra-
coronary imaging is to be performed, it is appropriate to carry out this imaging at the time of the acute cardiac catheterization, after diagnostic angiog-
raphy. Patients should be made aware of the additional information the test can provide and the small increase in risk associated with intracoronary
imaging.
1 • Provocative testing for coronary artery spasm might be considered in selected patients with a recent AMI with suspected vasospas-
tic angina. Provocative manoeuvres have to be always performed by operators with experience and not necessarily in the acute phase
of STEMI.
2 • Clinically suspected myocarditis by ESC Task Force criteria = No angiographic stenosis 50% plus non ischemic pattern on CMR.
Definite myocarditis by ESC Task Force criteria = No angiographic stenosis 50% plus endomyocardial biopsy confirmation (histology,
immunohistology, polymerase-chain reaction based techniques to search for genome of infectious agents, mainly viruses).
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(see Web Addenda). Quality indicators are intended to measure and
compare the quality of health service provision and serve as a founda-
tion for quality improvement initiatives.476 Proposed quality indica-
tors to assess the quality of the care for patients are presented in
Table 11.
Expanded text about quality indicators can be found in the Web
Addenda.
11. Gaps in the evidence and areas
for future research
Despite the great advances in STEMI management over recent deca-
des, important areas of uncertainty persist that should be explored in
the future. Here, we identify some, but not all, specific areas that
should be addressed within the next few years.
Table 11 Quality indicators
ACE = angiotensin-converting enzyme; ARB = angiotensin II receptor blocker; DAPT = dual antiplatelet therapy; ECG = electrocardiogram; GRACE = Global Registry of
Acute Coronary Events; IRA = Infarct-related artery; LVEF = left ventricular ejection fraction; PCI = percutaneous coronary intervention; STEMI = ST-segment elevation myo-
cardial infarction.
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Public awareness and emergency care
The very early stages of STEMI are the most vulnerable time, when
most sudden cardiac deaths occur. Public campaigns aiming to
increase early alerting of patients with ischaemic symptoms should
clearly state that the safest way to alert is to call the EMS. While
selected centres and geographic areas have made great progress in
ensuring high-quality rapid care for STEMI patients with routine pre-
alert of the interventional team, there remains a need for streamlining
of (pre-)hospital management in a homogeneous fashion worldwide,
including rural areas. Educational programmes and cross-country
exchange of experiences should help in this matter.
The selection of a 120 min from STEMI diagnosis to PCI-mediated
reperfusion as the cut-off to choose PCI or fibrinolysis is based on
relatively old registries and trials with different treatment strategies
from those presented in this document. The identification of the best
cut-off timing to choose a strategy is of extreme importance.
Reduction of ischaemia/reperfusion
injury
Final infarct size is one of the best predictors of long-term adverse
events in STEMI survivors. The introduction of a specific infarct-
limiting therapy in clinical practice might have a massive clinical and
socioeconomic impact. Several strategies, including pharmacological
and mechanical therapies, have shown a reduction of infarct size by
reducing ischaemia/reperfusion injury (including MVO) in experimen-
tal and small-scale clinical trials, but to date no large trial has demon-
strated a clinical benefit. One potential reason for this poor
translation is the difficulty of securing funds to conduct proper large-
scale clinical trials in this context.
Refinement of (acute and long-term)
antithrombotic regimes
Antithrombotic therapy is the cornerstone of the pharmacological
approach in STEMI. Despite major recent advances, important ques-
tions remain unaddressed. What is the best acute and maintenance
antithrombotic regimen in patients who have an indication for oral
anticoagulants? What is the best timing for the loading dose of oral
P2Y12 inhibitors and what are the best strategies for i.v. antithrom-
botic therapies? What is the role of potent P2Y12 inhibitors in
patients undergoing fibrinolysis? What is the real role of aspirin in this
new era of potent antiplatelet agents and low dose anticoagulation?
What is the best duration of maintenance therapy with P2Y12 inhibi-
tors as single or multiple antithrombotic regimens?
Beta-blockers and ACE inhibitors
Although research regarding these classes of drugs was intense sev-
eral decades ago, more recently, there has been a lack of properly
powered clinical trials. The best timing for initiation (and route of
administration) of beta-blockers is still not well established. The role
of maintenance beta-blocker therapy is well established for patients
with heart failure and/or low LVEF, but its clinical value for the rest of
STEMI has not been prospectively tested in dedicated clinical trials of
reperfused patients. Similar limitations apply to the use of mainte-
nance ACE inhibitors.
Post-STEMI risk stratification
The optimal therapeutic strategy to minimize the risk of sudden
death in patients who develop VT or VF during or early after STEMI
is not entirely clear. Despite the clinical benefit of ICDs in patients
with low LVEF and reduced functional class weeks after STEMI being
well established, there is a need for better sudden death risk stratifi-
cation algorithms.
The best management of non-IRA lesions should be addressed.
Unresolved issues are the best criteria to guide PCI (angiography,
FFR, or assessment of plaque vulnerability) and the best timing for
complete revascularization if indicated (during index PCI or staged,
including staged during hospitalization vs. after discharge).
Shock and left ventricular assist devices
Severe heart failure and shock are among the most important nega-
tive prognostic predictors in patients with STEMI. In addition to
urgent revascularization of IRA and standard medical therapies for
pre- and afterload reduction, there is limited evidence for the system-
atic use of inotropic and vasopressor agents as well as mechanical
support. Similarly, the benefit of routine complete revascularization
during the index PCI procedure has not been formally demonstrated.
The use of IABP has not met prior expectations of benefit, while LV
assist devices and ECMO are increasingly popular but have not been
sufficiently evaluated in clinical trials. Systematic evaluation of phar-
macological and interventional strategies and LV assist devices for
patients with shock are urgently needed.
Myocardial repair/rescue
The effectiveness and safety of novel therapies able to replace dead
myocardium or prevent poor remodelling (e.g. cell therapy or gene
therapy) is an unfulfilled promise. There is a strong need for basic
research studies to better understand the biological processes
involved in cardiac development and repair, in order for these to be
strong grounds to translate studies into clinically relevant animal
models and finally into humans.
Need for observational data and real-
world evidence
In order to understand shortcomings and challenges in clinical prac-
tice, for quality assessment and for benchmarking, unselected and
validated registries and clinical databases are needed. In this docu-
ment, we have specified quality indicators intended to measure and
compare the quality of health service provision and serve as a founda-
tion for quality improvement initiatives. Their effects on procedural
and clinical outcomes need to be evaluated.
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..Need for pragmatic real-life clinical trials
One major limitation of highly selective controlled clinical trials is
their applicability in the real world. Strict inclusion criteria, tailored
management, and very close follow-up results in a bias that precludes
universal implementation. An opportunity is the implementation of
pragmatic clinical trials including registry-based randomized clinical
trials.477 These trials are less selective and less expensive alternatives
to classical ones, especially for therapies used in clinical practice.
12. Key messages
(1) Epidemiology of STEMI: Although the rate of mortality associated
with ischaemic heart disease have reduced in Europe over the last
few decades, this is still the single most common cause of death
worldwide. The relative incidences of STEMI and NSTEMI are
decreasing and increasing, respectively. Despite the decline in
acute and long-term death associated with STEMI, in parallel with
the widespread use of reperfusion, mortality remains substantial.
The in-hospital mortality rates of unselected patients with STEMI
in national European registries vary between 4–12%.
(2) Gender aspects: Women tend to receive reperfusion therapy and
other evidence-based treatments less frequently and/or in a
delayed way than men. It is important to highlight that women and
men receive equal benefit from a reperfusion and other STEMI-
related therapies, and so both genders must be managed equally.
(3) ECG and STEMI diagnosis: In some cases, patients may have coro-
nary artery occlusion/global ischaemia in the absence of character-
istic ST elevation (e.g. bundle branch block, ventricular pacing,
hyperacute T-waves, isolated ST-depression in anterior leads, and/
or universal ST depression with ST-elevation in aVR). In patients
with the mentioned ECG changes and clinical presentation com-
patible with ongoing myocardial ischaemia, a primary PCI strategy
(i.e. urgent angiography and PCI if indicated) should be followed.
(4) Reperfusion strategy selection: STEMI diagnosis (defined as the
time at which the ECG of a patient with ischaemic symptoms is
interpreted as presenting ST-segment elevation or equivalent) is
the time zero in the reperfusion strategy clock. STEMI patients
should undergo a primary PCI strategy unless the anticipated abso-
lute time from STEMI diagnosis to PCI-mediated reperfusion
is > 120 min, when fibrinolysis should be initiated immediately (i.e.
within 10 min of STEMI diagnosis).
(5) STEMI management networks: Coordination between EMS and
hospitals with common written protocols is at the centre of
STEMI management. EMS should transfer patients to 24/7 high-
volume PCI centres irrespective of whether the primary treatment
strategy is PCI or pre-hospital fibrinolysis. EMS should always alert
the PCI centre immediately after selection of the reperfusion strat-
egy. Patient transfer to the PCI centre should bypass the emer-
gency department.
(6) Cardiac arrest and reperfusion strategy: Patients with ST-elevation
on post-resuscitation ECG should undergo a primary PCI strategy.
In cases without ST-segment elevation on post-resuscitation ECG
but with a high suspicion of ongoing myocardial ischaemia, urgent
angiography should be done within 2 h after a quick evaluation to
exclude non-coronary causes. In all cases, the decision to perform
urgent coronary angiography should take into account factors
associated with poor neurological outcome.
(7) Technical aspects during primary PCI: Routine radial access and
routine DES implant is the standard of care during primary PCI.
Routine thrombus aspiration or deferred stenting are
contraindicated.
(8) Management of non-IRA lesions: Treatment of severe stenosis
(evaluated either by angiography or FFR) should be considered
before hospital discharge (either immediately during the index PCI
or staged at a later time). In cardiogenic shock, non-IRA PCI should
be considered during the index procedure.
(9) Antithrombotic therapy: Anticoagulants and DAPT are the cor-
nerstone of the pharmacological approach in the acute phase of
STEMI. Primary PCI: unfractionated heparin (enoxaparin or bivalir-
udin may be alternatives), and loading dose of aspirin and prasu-
grel/ticagrelor. Fibrinolysis: enoxaparin (unfractionated heparin
may be alternative), and loading dose of aspirin and clopidogrel.
Maintenance therapy in the majority of patients is based on one
year DAPT in the form of aspirin plus prasugrel/ticagrelor.
(10) Early care: After reperfusion therapy, patients should be moni-
tored for at least 24 h. Early ambulation and early discharge are the
best option in uncomplicated patients. Consequently, time for
implementing secondary prevention is limited highlighting the
importance of close collaboration between all stakeholders.
(11) Special patient subsets: Patients taking oral anticoagulants with
renal insufficiency and/or the elderly represent a challenge in terms
of optimal antithrombotic therapy. Special attention should be
paid to dose adjustment of some pharmacological strategies in
these subsets. Patients with diabetes and those not undergoing
reperfusion represent another subset of patients that require addi-
tional attention.
(12) Imaging in STEMI: Non-invasive imaging is very important for the
acute and long-term management of STEMI patients.
(13) MINOCA: A sizeable proportion of STEMI patients do not present
significant coronary artery stenosis on urgent angiography. It is
important to perform additional diagnostic tests in these patients
to identify the aetiology and tailor appropriate therapy, which may
be different from typical STEMI.
(14) Quality indicators: In some cases, there is a gap between optimal
guideline-based treatment and actual care of STEMI patients. In
order to reduce this gap, it is important to measure established
quality indicators to audit practice and improve outcomes in real-
life. The use of well-defined and validated quality indicators to
measure and improve STEMI care is recommended.
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13. Evidenced-based ‘to do and not to do’ messages from the Guidelines
Recommendations
Recommendations for initial diagnosis Classa Levelb
Twelve-lead ECG recording and interpretation is indicated as soon as possible at the point of FMC, with a maximum target
delay of 10 min.
I B
ECG monitoring with defibrillator capacity is indicated as soon as possible in all patients with suspected STEMI. I B
Recommendations for relief of hypoxaemia and symptoms
Routine oxygen is not recommended in patients with SaO2 90%. III B
Recommendations for cardiac arrest
A primary PCI strategy is recommended in patients with resuscitated cardiac arrest and an ECG consistent with STEMI. I B
Targeted temperature management is indicated early after resuscitation of cardiac arrest patients who remain unresponsive. I B
Pre-hospital cooling using a rapid infusion of large volumes of cold i.v. fluid immediately after return of spontaneous circulation
is not recommended.
III B
Recommendations for logistics of pre-hospital care
It is recommended that the pre-hospital management of STEMI patients is based on regional networks designed to deliver
reperfusion therapy expeditiously and effectively, with efforts made to make primary PCI available to as many patients as
possible.
I B
It is recommended that primary PCI-capable centres deliver a 24/7 service and are able to perform primary PCI without delay. I B
It is recommended that patients transferred to a PCI-capable centre for primary PCI bypass the emergency department and
CCU/ICCU and are transferred directly to the catheterization laboratory.
I B
Recommendations for reperfusion therapy
Reperfusion therapy is indicated in all patients with symptoms of ischaemia of <_ 12 h duration and persistent ST-segment
elevation.
I A
If primary PCI cannot be performed in a timely way after STEMI diagnosis, fibrinolytic therapy is recommended within 12 h of
symptom onset in patients without contraindications.
I A
In asymptomatic patients, routine PCI of an occluded IRA >48 h after onset of STEMI is not indicated. III A
Recommendations for procedural aspects of the primary PCI strategy
Primary PCI of the IRA is indicated. I A
Stenting is recommended (over balloon angioplasty) for primary PCI. I A
Stenting with new-generation DES is recommended over BMS for primary PCI. I A
Radial access is recommended over femoral access if performed by an experienced radial operator. I A
Routine use of thrombus aspiration is not recommended. III A
Routine use of deferred stenting is not recommended. III B
Recommendations for periprocedural and post-procedural antithrombotic therapy in patients undergoing primary PCI
A potent P2Y12 inhibitor (prasugrel or ticagrelor), or clopidogrel if these are not available or are contraindicated, is recom-
mended before (or at latest at the time of) PCI and maintained over 12 months unless there are contraindications such as
excessive risk of bleeding.
I A
Continued
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Aspirin oral or i.v. (if unable to swallow) is recommended as soon as possible for all patients without contraindications. I B
Fondaparinux is not recommended for primary PCI. III B
Recommendations for Fibrinolytic therapy
When fibrinolysis is the reperfusion strategy, it is recommended to initiate this treatment as soon as possible after STEMI diag-
nosis, preferably in the pre-hospital setting.
I A
A fibrin-specific agent (i.e. tenecteplase, alteplase, or reteplase) is recommended. I B
Oral or i.v. aspirin is indicated. I B
Clopidogrel is indicated in addition to aspirin. I A
Anticoagulation is recommended in patients treated with lytics until revascularization (if performed) or for the duration of hos-
pital stay up to 8 days. The anticoagulant can be:
I A
 Enoxaparin i.v. followed by s.c. (preferred over UFH). I A
 UFH given as a weight-adjusted i.v. bolus followed by infusion. I B
Transfer to a PCI-capable centre following fibrinolysis is indicated in all patients immediately after fibrinolysis. I A
Emergency angiography and PCI if indicated is recommended in patients with heart failure/shock. I A
Rescue PCI is indicated immediately when fibrinolysis has failed (<50% ST-segment resolution at 60–90 min) or at any time in
the presence of haemodynamic or electrical instability, or worsening ischaemia.
I A
Angiography and PCI of the IRA, if indicated, is recommended between 2–24 h after successful fibrinolysis. I A
Emergency angiography and PCI if needed is indicated in the case of recurrent ischaemia or evidence of reocclusion after initial
successful fibrinolysis.
I B
Recommendations for imaging and stress testing in STEMI patients
Routine echocardiography during hospital stay to assess resting LV and RV function, detect early post-MI mechanical complica-
tions, and exclude LV thrombus is recommended in all patients.
I B
Recommendations for behavioural aspects after STEMI
It is recommended to identify smokers and provide repeated advice on stopping, with offers to help with the use of follow-up
support, nicotine replacement therapies, varenicline, and bupropion individually or in combination.
I A
Participation in a cardiac rehabilitation programme is recommended. I A
Recommendations for maintenance antithrombotic strategy after STEMI
Antiplatelet therapy with low-dose aspirin (75–100 mg) is indicated. I A
DAPT in the form of aspirin plus ticagrelor or prasugrel (or clopidogrel if ticagrelor or prasugrel are not available or are contra-
indicated) is recommended for 12 months after PCI, unless there are contraindications such as excessive risk of bleeding.
I A
A PPI in combination with DAPT is recommended in patients at high risk of gastrointestinal bleeding. I B
Recommendations for routine therapies in the acute, subacute, and long-term phases
Oral treatment with beta-blockers is indicated in patients with heart failure and/or LVEF <_40% unless contraindicated. I A
Intravenous beta-blockers must be avoided in patients with hypotension, acute heart failure, or AV block or severe bradycardia. III B
It is recommended to start high-intensity statin therapy as early as possible, unless contraindicated, and maintain it long-term. I A
An LDL-C goal of < 1.8 mmol/L (70 mg/dL) or a reduction of at least 50% if the baseline LDL-C is between 1.8–3.5 mmol/L
(70–135 mg/dL) is recommended.
I B
ACE inhibitors are recommended, starting within the first 24 h of STEMI in patients with evidence of heart failure, LV systolic
dysfunction, diabetes, or an anterior infarct. I A
Continued
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14. Web addenda
All Web figures and Web tables are available in the online Web
Addenda at: European Heart Journal online and also via the ESC
Website at: https://www.escardio.org/Guidelines/Clinical-Practice-
Guidelines/Acute-Myocardial-Infarction-in-patients-presenting-with-
ST-segment-elevation-Ma
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An ARB, preferably valsartan, is an alternative to ACE inhibitors in patients with heart failure and/or LV systolic dysfunction,
particularly those who are intolerant of ACE inhibitors.
I B
MRAs are recommended in patients with an ejection fraction <_40% and heart failure or diabetes, who are already receiving an
ACE inhibitor and a beta-blocker, provided there is no renal failure or hyperkalaemia.
I B
Recommendations for the management of LV dysfunction and acute heart failure in STEMI
ACE inhibitor (or if not tolerated, ARB) therapy is indicated as soon as haemodynamically stable for all patients with evidence
of LVEF <_40% and/or heart failure to reduce the risk of hospitalization and death.
I A
Beta-blocker therapy is recommended in patients with LVEF <_40% and/or heart failure after stabilization, to reduce the risk of
death, recurrent MI, and hospitalization for heart failure.
I A
An MRA is recommended in patients with heart failure and LVEF <_40% with no severe renal failure or hyperkalaemia to reduce
the risk of cardiovascular hospitalization and death.
I B
Recommendations for the management of cardiogenic shock in STEMI
Immediate PCI is indicated for patients with cardiogenic shock if coronary anatomy is suitable. If coronary anatomy is not suit-
able for PCI, or PCI has failed, emergency CABG is recommended.
I B
Routine intra-aortic balloon pumping is not indicated. III B
Recommendations for management of atrial fibrillation
Digoxin is ineffective in converting recent onset AF to sinus rhythm and is not indicated for rhythm control. III A
Calcium channel blockers and beta-blockers including sotalol are ineffective in converting recent onset AF to sinus rhythm. III B
Prophylactic treatment with antiarrhythmic drugs to prevent AF is not indicated. III B
Recommendations for management of ventricular arrhythmias and conduction disturbances in the acute phase
Intravenous beta-blocker treatment is indicated for patients with polymorphic VT and/or VF unless contraindicated. I B
Prophylactic treatment with antiarrhythmic drugs is not indicated and may be harmful. III B
Recommendations for long-term management of ventricular arrhythmias and risk evaluation for sudden death
ICD therapy is recommended to reduce sudden cardiac death in patients with symptomatic heart failure (New York Heart
Association class II–III) and LVEF <_35%, despite optimal medical therapy for >3 months and at least 6 weeks after MI, who are
expected to survive for at least 1 year with good functional status.
I A
Recommendations with a class I or III and a level of evidence A or B. See ‘Abbreviations and acronyms’ list for explanation of abbreviations.
aClass of recommendation.
bLevel of evidence.
168 ESC Guidelines
Downloaded from https://academic.oup.com/eurheartj/article-abstract/39/2/119/4095042
by E-Library Insel user
on 07 February 2018
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
.
Ibrahimov; Belarus: Belorussian Scientific Society of Cardiologists,
Volha Sujayeva; Belgium: Belgian Society of Cardiology, Christophe
Beauloye; Bosnia and Herzegovina: Association of Cardiologists
of Bosnia and Herzegovina, Larisa Dizdarevic-Hudic; Bulgaria:
Bulgarian Society of Cardiology, Kiril Karamfiloff; Croatia: Croatian
Cardiac Society, Bosko Skoric; Cyprus: Cyprus Society of
Cardiology, Loizos Antoniades; Czech Republic: Czech Society of
Cardiology, Petr Tousek; Denmark: Danish Society of Cardiology,
Christian Juhl Terkelsen; Egypt: Egyptian Society of Cardiology,
Sameh Mohamad Shaheen; Estonia: Estonian Society of Cardiology,
Toomas Marandi; Finland: Finnish Cardiac Society, Matti Niemel€a;
The Former Yugoslav Republic of Macedonia: Macedonian
Society of Cardiology, Sasko Kedev; France: French Society of
Cardiology, Martine Gilard; Georgia: Georgian Society of
Cardiology, Alexander Aladashvili; Germany: German Cardiac
Society, Albrecht Elsaesser; Greece: Hellenic Society of Cardiology,
Ioannis Georgios Kanakakis; Hungary: Hungarian Society of
Cardiology, Béla Merkely; Iceland: Icelandic Society of Cardiology,
Thorarinn Gudnason; Israel: Israel Heart Society, Zaza Iakobishvili;
Italy: Italian Federation of Cardiology, Leonardo Bolognese;
Kazakhstan: Association of Cardiologists of Kazakhstan, Salim
Berkinbayev; Kosovo: Kosovo Society of Cardiology, Gani Bajraktari;
Kyrgyzstan: Kyrgyz Society of Cardiology, Medet Beishenkulov;
Latvia: Latvian Society of Cardiology, Ilja Zake; Libya: Libyan
Cardiac Society, Hisham Ben Lamin; Lithuania: Lithuanian Society
of Cardiology, Olivija Gustiene; Luxembourg: Luxembourg Society
of Cardiology, Bruno Pereira; Malta: Maltese Cardiac Society,
Robert G. Xuereb; Morocco: Moroccan Society of Cardiology,
Samir Ztot; Norway: Norwegian Society of Cardiology, Vibeke
Juliebø; Poland: Polish Cardiac Society, Jacek Legutko; Portugal:
Portuguese Society of Cardiology, Ana Teresa Timoteo; Romania:
Romanian Society of Cardiology, Gabriel Tatu-Chiţoiu; Russian
Federation: Russian Society of Cardiology, Alexey Yakovlev; San
Marino: San Marino Society of Cardiology, Luca Bertelli; Serbia:
Cardiology Society of Serbia, Milan Nedeljkovic; Slovakia: Slovak
Society of Cardiology, Martin Studencan; Slovenia: Slovenian
Society of Cardiology, Matjaz Bunc; Spain: Spanish Society of
Cardiology, Ana Maria Garcıa de Castro; Sweden: Swedish Society
of Cardiology, Petur Petursson; Switzerland: Swiss Society of
Cardiology, Raban Jeger; Tunisia: Tunisian Society of Cardiology and
Cardio-Vascular Surgery, Mohamed Sami Mourali; Turkey: Turkish
Society of Cardiology, Aylin Yildirir; Ukraine: Ukrainian Association
of Cardiology, Alexander Parkhomenko; United Kingdom: British
Cardiovascular Society, Chris P. Gale.
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